WO2011063159A1 - Compounds and methods for kinase modulation, and indications therefor - Google Patents
Compounds and methods for kinase modulation, and indications therefor Download PDFInfo
- Publication number
- WO2011063159A1 WO2011063159A1 PCT/US2010/057293 US2010057293W WO2011063159A1 WO 2011063159 A1 WO2011063159 A1 WO 2011063159A1 US 2010057293 W US2010057293 W US 2010057293W WO 2011063159 A1 WO2011063159 A1 WO 2011063159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- difluoro
- fluoro
- lower alkyl
- pyrrolo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 444
- 238000000034 method Methods 0.000 title claims abstract description 70
- 108091000080 Phosphotransferase Proteins 0.000 title description 39
- 102000020233 phosphotransferase Human genes 0.000 title description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 140
- 201000010099 disease Diseases 0.000 claims abstract description 134
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 208000002193 Pain Diseases 0.000 claims abstract description 41
- 230000035755 proliferation Effects 0.000 claims abstract description 37
- 201000001441 melanoma Diseases 0.000 claims abstract description 22
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 20
- 206010018338 Glioma Diseases 0.000 claims abstract description 20
- 206010003571 Astrocytoma Diseases 0.000 claims abstract description 19
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims abstract description 19
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims abstract description 19
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 19
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 19
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 19
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 15
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims abstract description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 15
- 208000005298 acute pain Diseases 0.000 claims abstract description 15
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims abstract description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 14
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 14
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 14
- 201000009036 biliary tract cancer Diseases 0.000 claims abstract description 14
- 208000020790 biliary tract neoplasm Diseases 0.000 claims abstract description 14
- 201000010175 gallbladder cancer Diseases 0.000 claims abstract description 14
- 201000007270 liver cancer Diseases 0.000 claims abstract description 14
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 14
- 201000005202 lung cancer Diseases 0.000 claims abstract description 14
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 14
- 208000030761 polycystic kidney disease Diseases 0.000 claims abstract description 14
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 567
- 125000001153 fluoro group Chemical group F* 0.000 claims description 503
- 125000003545 alkoxy group Chemical group 0.000 claims description 307
- -1 chloro, bromo, iodo Chemical group 0.000 claims description 273
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 149
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 118
- 229910052739 hydrogen Inorganic materials 0.000 claims description 110
- 239000001257 hydrogen Substances 0.000 claims description 103
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 96
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 94
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 66
- 230000001404 mediated effect Effects 0.000 claims description 63
- 125000001072 heteroaryl group Chemical group 0.000 claims description 57
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 52
- 229910052757 nitrogen Inorganic materials 0.000 claims description 48
- 229910052740 iodine Inorganic materials 0.000 claims description 47
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 44
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 229910052731 fluorine Inorganic materials 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 239000011737 fluorine Substances 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 150000002431 hydrogen Chemical group 0.000 claims description 21
- 201000009623 Myopathy Diseases 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 208000021642 Muscular disease Diseases 0.000 claims description 15
- 230000007812 deficiency Effects 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000005747 tumor angiogenesis Effects 0.000 claims description 12
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 230000005856 abnormality Effects 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 210000002307 prostate Anatomy 0.000 claims description 9
- 206010067380 Costello Syndrome Diseases 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 8
- 108010066684 Proto-Oncogene Proteins A-raf Proteins 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 8
- SJXWUCRWMDHAQR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(C5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 SJXWUCRWMDHAQR-UHFFFAOYSA-N 0.000 claims description 8
- 201000004931 neurofibromatosis Diseases 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 208000000094 Chronic Pain Diseases 0.000 claims description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000002458 carcinoid tumor Diseases 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- 208000028591 pheochromocytoma Diseases 0.000 claims description 7
- 201000006845 reticulosarcoma Diseases 0.000 claims description 7
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 206010058019 Cancer Pain Diseases 0.000 claims description 6
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 210000000232 gallbladder Anatomy 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 201000008319 inclusion body myositis Diseases 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 206010028417 myasthenia gravis Diseases 0.000 claims description 6
- RXVSJIUWPQDZHM-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropoxy)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(OCC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 RXVSJIUWPQDZHM-UHFFFAOYSA-N 0.000 claims description 6
- KYWSYAMZKOEFFP-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropyl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(CC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 KYWSYAMZKOEFFP-UHFFFAOYSA-N 0.000 claims description 6
- KJQUSUVKIGOFGQ-UHFFFAOYSA-N n-[3-(4-ethoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OCC)N=CN=C3NC=2)=C1F KJQUSUVKIGOFGQ-UHFFFAOYSA-N 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 210000001685 thyroid gland Anatomy 0.000 claims description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 5
- 208000002016 Adenosine monophosphate deaminase deficiency Diseases 0.000 claims description 5
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 5
- 208000015374 Central core disease Diseases 0.000 claims description 5
- 201000003728 Centronuclear myopathy Diseases 0.000 claims description 5
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 5
- 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims description 5
- 108700043208 Dimauro disease Proteins 0.000 claims description 5
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims description 5
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 5
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 5
- 206010019196 Head injury Diseases 0.000 claims description 5
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 claims description 5
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 5
- 208000027747 Kennedy disease Diseases 0.000 claims description 5
- 108700006394 Lactate Dehydrogenase Deficiency Proteins 0.000 claims description 5
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 5
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 5
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 208000010316 Myotonia congenita Diseases 0.000 claims description 5
- 208000012905 Myotonic disease Diseases 0.000 claims description 5
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 5
- 208000034965 Nemaline Myopathies Diseases 0.000 claims description 5
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 5
- 108700010203 Phosphoglycerate Kinase 1 Deficiency Proteins 0.000 claims description 5
- 102000009097 Phosphorylases Human genes 0.000 claims description 5
- 108010073135 Phosphorylases Proteins 0.000 claims description 5
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 claims description 5
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 5
- 208000032978 Structural Congenital Myopathies Diseases 0.000 claims description 5
- 208000035954 Thomsen and Becker disease Diseases 0.000 claims description 5
- 102000004357 Transferases Human genes 0.000 claims description 5
- 108090000992 Transferases Proteins 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 230000001780 adrenocortical effect Effects 0.000 claims description 5
- 201000006960 adult spinal muscular atrophy Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 210000000013 bile duct Anatomy 0.000 claims description 5
- 210000003445 biliary tract Anatomy 0.000 claims description 5
- 229960004203 carnitine Drugs 0.000 claims description 5
- 201000007303 central core myopathy Diseases 0.000 claims description 5
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 5
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 201000009338 distal myopathy Diseases 0.000 claims description 5
- 230000002124 endocrine Effects 0.000 claims description 5
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 5
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 5
- 201000009339 glycogen storage disease VII Diseases 0.000 claims description 5
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 201000006913 intermediate spinal muscular atrophy Diseases 0.000 claims description 5
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 230000009756 muscle regeneration Effects 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 230000003274 myotonic effect Effects 0.000 claims description 5
- GLGPANKFKJBAGU-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-propan-2-yl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=2C(C(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F GLGPANKFKJBAGU-UHFFFAOYSA-N 0.000 claims description 5
- GQDPNDGMRMXBGK-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethoxy)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(OCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 GQDPNDGMRMXBGK-UHFFFAOYSA-N 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 5
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 5
- 230000002981 neuropathic effect Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 claims description 5
- 208000029308 periodic paralysis Diseases 0.000 claims description 5
- 210000000578 peripheral nerve Anatomy 0.000 claims description 5
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000001076 sarcopenia Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 5
- 208000032521 type II spinal muscular atrophy Diseases 0.000 claims description 5
- 208000005606 type IV spinal muscular atrophy Diseases 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000036075 Autosomal dominant tubulointerstitial kidney disease Diseases 0.000 claims description 4
- 201000002829 CREST Syndrome Diseases 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000012239 Developmental disease Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000025309 Hair disease Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 4
- 206010029748 Noonan syndrome Diseases 0.000 claims description 4
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000025844 Prostatic disease Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 208000030172 endocrine system disease Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000028774 intestinal disease Diseases 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- HDXQEGCYNDHKHC-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OC)N=CN=C3NC=2)=C1F HDXQEGCYNDHKHC-UHFFFAOYSA-N 0.000 claims description 4
- SDRCNWBWQLUMIF-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 SDRCNWBWQLUMIF-UHFFFAOYSA-N 0.000 claims description 4
- SBOWWRAEFKKHTA-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-propan-2-ylbenzenesulfonamide Chemical compound C1=CC(C(C)C)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)N=CN=C3NC=2)=C1F SBOWWRAEFKKHTA-UHFFFAOYSA-N 0.000 claims description 4
- URXLQJODCOVBQC-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)N=CN=C3NC=2)=C1F URXLQJODCOVBQC-UHFFFAOYSA-N 0.000 claims description 4
- ZPEFGHWVELTBKX-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-2-fluorobenzenesulfonamide Chemical compound C1=2C(O)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1F ZPEFGHWVELTBKX-UHFFFAOYSA-N 0.000 claims description 4
- KXKVLMOSRGNQCB-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(O)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 KXKVLMOSRGNQCB-UHFFFAOYSA-N 0.000 claims description 4
- VMFPIDBYAMRWMW-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(O)N=CN=C3NC=2)=C1F VMFPIDBYAMRWMW-UHFFFAOYSA-N 0.000 claims description 4
- CDCCJJDIKJZUGO-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-propan-2-yl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(C(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 CDCCJJDIKJZUGO-UHFFFAOYSA-N 0.000 claims description 4
- RXMFZXLFBJEGAH-UHFFFAOYSA-N n-[3-(4-chloro-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)N=CN=C3NC=2)=C1F RXMFZXLFBJEGAH-UHFFFAOYSA-N 0.000 claims description 4
- VYWPIWIONRKEEM-UHFFFAOYSA-N n-[3-(4-chloro-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(Cl)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 VYWPIWIONRKEEM-UHFFFAOYSA-N 0.000 claims description 4
- DCLSEMSHYVMKNE-UHFFFAOYSA-N n-[3-(4-ethoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(OCC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 DCLSEMSHYVMKNE-UHFFFAOYSA-N 0.000 claims description 4
- 201000002648 nephronophthisis Diseases 0.000 claims description 4
- 201000009925 nephrosclerosis Diseases 0.000 claims description 4
- 210000000933 neural crest Anatomy 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 208000028589 polycystic liver disease Diseases 0.000 claims description 4
- 230000037390 scarring Effects 0.000 claims description 4
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 4
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- MLJMHUPNBHGAHT-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropyl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(CC(C)C)N=CN=C3NC=2)=C1F MLJMHUPNBHGAHT-UHFFFAOYSA-N 0.000 claims description 3
- ZGFZSONHOORALY-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(trifluoromethyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(C=CN=C3NC=2)C(F)(F)F)C(F)=CC=C1NS(=O)(=O)C1=CC=CC=C1 ZGFZSONHOORALY-UHFFFAOYSA-N 0.000 claims description 3
- WLPFZVLMFBVNJD-UHFFFAOYSA-N n-[3-(4-chloro-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)N=CN=C3NC=2)=C1F WLPFZVLMFBVNJD-UHFFFAOYSA-N 0.000 claims description 3
- SSKPOKDFXKFMII-UHFFFAOYSA-N n-[3-(4-chloro-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)N=CN=C3NC=2)=C1F SSKPOKDFXKFMII-UHFFFAOYSA-N 0.000 claims description 3
- SFHPGRLOFYABKA-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethoxy)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(OCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 SFHPGRLOFYABKA-UHFFFAOYSA-N 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 125000006224 2-tetrahydrofuranylmethyl group Chemical group [H]C([H])(*)C1([H])OC([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 229910003204 NH2 Inorganic materials 0.000 claims description 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- FTGAYAUISOZPMW-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-2-methylpropane-1-sulfonamide Chemical compound C1=2C(OC)=NC=NC=2NC=C1C(=O)C1=C(F)C=CC(NS(=O)(=O)CC(C)C)=C1F FTGAYAUISOZPMW-UHFFFAOYSA-N 0.000 claims description 2
- KQOCOFXSXRGZPT-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-3,5-dimethylbenzenesulfonamide Chemical compound C1=2C(OC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(C)=CC(C)=C1 KQOCOFXSXRGZPT-UHFFFAOYSA-N 0.000 claims description 2
- PFIIFWSYZSZPOA-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-ethylbenzenesulfonamide Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OC)N=CN=C3NC=2)=C1F PFIIFWSYZSZPOA-UHFFFAOYSA-N 0.000 claims description 2
- LSUINUMCDVVIOG-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-propan-2-ylbenzenesulfonamide Chemical compound C1=2C(OC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(C)C)C=C1 LSUINUMCDVVIOG-UHFFFAOYSA-N 0.000 claims description 2
- SORRSVSKYMCMAT-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-6-methoxypyridine-3-sulfonamide Chemical compound C1=NC(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OC)N=CN=C3NC=2)=C1F SORRSVSKYMCMAT-UHFFFAOYSA-N 0.000 claims description 2
- HXISVVNUCPIGFF-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)N=CN=C3NC=2)=C1F HXISVVNUCPIGFF-UHFFFAOYSA-N 0.000 claims description 2
- WMKLPBXKOPVVJT-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-3,5-dimethylbenzenesulfonamide Chemical compound CC1=CC(C)=CC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(C)N=CN=C4NC=3)C(F)=CC=2)F)=C1 WMKLPBXKOPVVJT-UHFFFAOYSA-N 0.000 claims description 2
- JMADVECBUYWJMG-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-ethylbenzenesulfonamide Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)N=CN=C3NC=2)=C1F JMADVECBUYWJMG-UHFFFAOYSA-N 0.000 claims description 2
- UNIBAJXVTCZHIL-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=2C(O)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F UNIBAJXVTCZHIL-UHFFFAOYSA-N 0.000 claims description 2
- VOOBWXWZJRRSOP-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(O)N=CN=C3NC=2)=C1F VOOBWXWZJRRSOP-UHFFFAOYSA-N 0.000 claims description 2
- XUJXDVNWPVYWGI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(trifluoromethyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(C=CN=C3NC=2)C(F)(F)F)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 XUJXDVNWPVYWGI-UHFFFAOYSA-N 0.000 claims description 2
- PTJZMDMBXPEXCS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(trifluoromethyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C=CN=C3NC=2)C(F)(F)F)=C1F PTJZMDMBXPEXCS-UHFFFAOYSA-N 0.000 claims description 2
- IYKDJGMGGIASRF-UHFFFAOYSA-N n-[3-(4-chloro-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(Cl)N=CN=C4NC=3)C(F)=CC=2)F)=C1 IYKDJGMGGIASRF-UHFFFAOYSA-N 0.000 claims description 2
- CWNRFSHKYZGRGP-UHFFFAOYSA-N n-[3-(4-cyano-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(C#N)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 CWNRFSHKYZGRGP-UHFFFAOYSA-N 0.000 claims description 2
- SGZOPEYKUQTYTB-UHFFFAOYSA-N n-[3-(4-ethoxy-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OCC)N=CN=C3NC=2)=C1F SGZOPEYKUQTYTB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- MABAIMZGUCLCLC-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-3-fluoro-4-methoxybenzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)N=CN=C3NC=2)=C1F MABAIMZGUCLCLC-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract description 119
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract description 118
- 102000001253 Protein Kinase Human genes 0.000 abstract description 62
- 108060006633 protein kinase Proteins 0.000 abstract description 62
- 230000000694 effects Effects 0.000 abstract description 52
- 238000009472 formulation Methods 0.000 abstract description 10
- 208000022371 chronic pain syndrome Diseases 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 125000001424 substituent group Chemical group 0.000 description 96
- 239000003112 inhibitor Substances 0.000 description 73
- 102000016914 ras Proteins Human genes 0.000 description 56
- 108010014186 ras Proteins Proteins 0.000 description 55
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 41
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 33
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 33
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 29
- 125000001246 bromo group Chemical group Br* 0.000 description 25
- 125000002346 iodo group Chemical group I* 0.000 description 25
- 230000035772 mutation Effects 0.000 description 25
- 108010077182 raf Kinases Proteins 0.000 description 24
- 102000009929 raf Kinases Human genes 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 101150019464 ARAF gene Proteins 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 125000004429 atom Chemical group 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 238000003674 kinase activity assay Methods 0.000 description 13
- 102100039788 GTPase NRas Human genes 0.000 description 12
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- YVYMBNSKXOXSKW-UHFFFAOYSA-N 1-Palmitoyl-2-hydroxy-sn-glycero-3-PE Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN YVYMBNSKXOXSKW-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- YRGPHRGZYCOXKX-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 YRGPHRGZYCOXKX-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 7
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 7
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 7
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 7
- 108091008605 VEGF receptors Proteins 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- ZJICLJYBROBWEO-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxetan-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4COC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 ZJICLJYBROBWEO-UHFFFAOYSA-N 0.000 description 7
- PKZPRENZGPKJSD-UHFFFAOYSA-N n-[3-[4-(cyclopentylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4CCCC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 PKZPRENZGPKJSD-UHFFFAOYSA-N 0.000 description 7
- OXXUVCZRQFCJCI-UHFFFAOYSA-N n-[3-[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CC4)N=CN=C3NC=2)=C1F OXXUVCZRQFCJCI-UHFFFAOYSA-N 0.000 description 7
- BMIPZELXUIKJRJ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 BMIPZELXUIKJRJ-UHFFFAOYSA-N 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- GAMKNLFIHBMGQT-UHFFFAOYSA-N 3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C GAMKNLFIHBMGQT-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 6
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- YRKOXWNRKOYKGI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=2C(NCC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F YRKOXWNRKOYKGI-UHFFFAOYSA-N 0.000 description 6
- ZBNHPVOQCUEROD-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 ZBNHPVOQCUEROD-UHFFFAOYSA-N 0.000 description 6
- FCLZRXKDPVCTQU-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(4-fluoroanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=CC(F)=CC=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C(=CC=C(F)C=3)F)C=CC=1F)F)=CN2 FCLZRXKDPVCTQU-UHFFFAOYSA-N 0.000 description 6
- MQWZUKBWBADKNN-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(methylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 MQWZUKBWBADKNN-UHFFFAOYSA-N 0.000 description 6
- TVUPOELBCAAPHE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxan-4-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4CCOCC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 TVUPOELBCAAPHE-UHFFFAOYSA-N 0.000 description 6
- GGPYYUMXGVJJGG-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxetan-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4COC4)N=CN=C3NC=2)=C1F GGPYYUMXGVJJGG-UHFFFAOYSA-N 0.000 description 6
- HROKYJWBXPRHSI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F HROKYJWBXPRHSI-UHFFFAOYSA-N 0.000 description 6
- LVUFHZLCMSVBCV-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NC=5C=NC=CC=5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 LVUFHZLCMSVBCV-UHFFFAOYSA-N 0.000 description 6
- OPQUHOSORPMZHW-UHFFFAOYSA-N n-[3-(4-amino-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(N)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 OPQUHOSORPMZHW-UHFFFAOYSA-N 0.000 description 6
- XWFPRLGIBOKERT-UHFFFAOYSA-N n-[3-[4-(benzylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC=5C=CC=CC=5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 XWFPRLGIBOKERT-UHFFFAOYSA-N 0.000 description 6
- LXLPDLHSRJAMCY-UHFFFAOYSA-N n-[3-[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 LXLPDLHSRJAMCY-UHFFFAOYSA-N 0.000 description 6
- GOYWXUNBCDZQBO-UHFFFAOYSA-N n-[3-[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 GOYWXUNBCDZQBO-UHFFFAOYSA-N 0.000 description 6
- RVCKQBHLGFIHTN-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 RVCKQBHLGFIHTN-UHFFFAOYSA-N 0.000 description 6
- GXDAAXUZVKFWGA-UHFFFAOYSA-N n-[3-[4-(ethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=2C(NCC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F GXDAAXUZVKFWGA-UHFFFAOYSA-N 0.000 description 6
- SIDKHUNHZPZHAX-UHFFFAOYSA-N n-[3-[4-(ethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 SIDKHUNHZPZHAX-UHFFFAOYSA-N 0.000 description 6
- AXUVFTOFFUHNSP-UHFFFAOYSA-N n-[3-[4-[(1,3-dimethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound CC1=NN(C)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C(=CC=C(F)C=3)F)C=CC=1F)F)=CN2 AXUVFTOFFUHNSP-UHFFFAOYSA-N 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- HBZAZSCNDMDWEU-WREZULKGSA-N 3,5-diamino-6-chloro-n-[n'-[4-[4-[2-[hexyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]amino]ethoxy]phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide Chemical compound C1=CC(OCCN(CCCCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C1CCCCNC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N HBZAZSCNDMDWEU-WREZULKGSA-N 0.000 description 5
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- SPMQKINJLHDBDK-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-hydroxyethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCCO)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 SPMQKINJLHDBDK-UHFFFAOYSA-N 0.000 description 5
- AMTCATHJFOUERO-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methoxyethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound C1=2C(NCCOC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1F AMTCATHJFOUERO-UHFFFAOYSA-N 0.000 description 5
- MRYMGLBVNAPHJO-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound C1=2C(NCC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1F MRYMGLBVNAPHJO-UHFFFAOYSA-N 0.000 description 5
- IMHSUZLLEUJTEX-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methoxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound COC1=CC=CC(NC=2C=3C(C(=O)C=4C(=C(NS(=O)(=O)C=5C(=CC=C(F)C=5)F)C=CC=4F)F)=CNC=3N=CN=2)=C1 IMHSUZLLEUJTEX-UHFFFAOYSA-N 0.000 description 5
- MPSVLLIYJALHDE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methoxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound COC1=CC=CC(NC=2C=3C(C(=O)C=4C(=C(NS(=O)(=O)C=5C(=CC=CC=5)F)C=CC=4F)F)=CNC=3N=CN=2)=C1 MPSVLLIYJALHDE-UHFFFAOYSA-N 0.000 description 5
- PLQVECJRVMVOKY-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxan-4-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCOCC4)N=CN=C3NC=2)=C1F PLQVECJRVMVOKY-UHFFFAOYSA-N 0.000 description 5
- PFZUFUIOCLROIE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxetan-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4COC4)N=CN=C3NC=2)=C1F PFZUFUIOCLROIE-UHFFFAOYSA-N 0.000 description 5
- ZWORQWXQCWAORP-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-ethylbenzenesulfonamide Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F ZWORQWXQCWAORP-UHFFFAOYSA-N 0.000 description 5
- QPDCSAJYXKIUTC-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-propan-2-ylbenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(C)C)C=C1 QPDCSAJYXKIUTC-UHFFFAOYSA-N 0.000 description 5
- ICONWTMNIXBZTO-UHFFFAOYSA-N n-[3-[4-(benzylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC=4C=CC=CC=4)N=CN=C3NC=2)=C1F ICONWTMNIXBZTO-UHFFFAOYSA-N 0.000 description 5
- OIQMIGBZOAYLNT-UHFFFAOYSA-N n-[3-[4-(cyclopentylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCCC4)N=CN=C3NC=2)=C1F OIQMIGBZOAYLNT-UHFFFAOYSA-N 0.000 description 5
- FCCQOVGHCZNBOX-UHFFFAOYSA-N n-[3-[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CC4)N=CN=C3NC=2)=C1F FCCQOVGHCZNBOX-UHFFFAOYSA-N 0.000 description 5
- VPBCLNNFDZXZED-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F VPBCLNNFDZXZED-UHFFFAOYSA-N 0.000 description 5
- KFVUUQPYCGRPRP-UHFFFAOYSA-N n-[3-[4-(dimethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(N(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 KFVUUQPYCGRPRP-UHFFFAOYSA-N 0.000 description 5
- BEAFFEVCSGXKRD-UHFFFAOYSA-N n-[3-[4-(ethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound C1=2C(NCC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1F BEAFFEVCSGXKRD-UHFFFAOYSA-N 0.000 description 5
- MZNUIROSGLQZKD-UHFFFAOYSA-N n-[3-[4-[(1,3-dimethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound CC1=NN(C)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C(=CC=CC=3)F)C=CC=1F)F)=CN2 MZNUIROSGLQZKD-UHFFFAOYSA-N 0.000 description 5
- VVARIPLFBATYLY-UHFFFAOYSA-N n-[3-[4-[(1-ethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C1=NN(CC)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C(=CC=C(F)C=3)F)C=CC=1F)F)=CN2 VVARIPLFBATYLY-UHFFFAOYSA-N 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 208000031223 plasma cell leukemia Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 4
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- KUEKDIBEMNSMDR-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1F KUEKDIBEMNSMDR-UHFFFAOYSA-N 0.000 description 4
- JTISGOUZHJUPEA-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=NC=CC=4)N=CN=C3NC=2)=C1F JTISGOUZHJUPEA-UHFFFAOYSA-N 0.000 description 4
- SBUBQOQJOMWCLQ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(1-methylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=NN(C)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C=CC=1F)F)=CN2 SBUBQOQJOMWCLQ-UHFFFAOYSA-N 0.000 description 4
- XVAVELHQXBKZDJ-UHFFFAOYSA-N n-[3-(4-anilino-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC=4C=CC=CC=4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 XVAVELHQXBKZDJ-UHFFFAOYSA-N 0.000 description 4
- VFZFKDJKAGKMCL-UHFFFAOYSA-N n-[3-(4-chloro-5-methoxy-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)C(OC)=CN=C3NC=2)=C1F VFZFKDJKAGKMCL-UHFFFAOYSA-N 0.000 description 4
- VJZWNKLIZFKCNT-UHFFFAOYSA-N n-[3-(4-chloro-5-methyl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)C(C)=CN=C3NC=2)=C1F VJZWNKLIZFKCNT-UHFFFAOYSA-N 0.000 description 4
- QENJFXWQPRBSQL-UHFFFAOYSA-N n-[3-(4-cyano-5-fluoro-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C#N)C(F)=CN=C3NC=2)=C1F QENJFXWQPRBSQL-UHFFFAOYSA-N 0.000 description 4
- PZFQWNDIYGXHLL-UHFFFAOYSA-N n-[3-(5-chloro-4-cyano-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(C#N)C(Cl)=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 PZFQWNDIYGXHLL-UHFFFAOYSA-N 0.000 description 4
- KEWQMBPIRFTITR-UHFFFAOYSA-N n-[3-(5-chloro-4-cyano-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C#N)C(Cl)=CN=C3NC=2)=C1F KEWQMBPIRFTITR-UHFFFAOYSA-N 0.000 description 4
- TVZVVHVCQHZYKX-UHFFFAOYSA-N n-[3-(5-chloro-4-methyl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(C)C(Cl)=CN=C3NC=2)=C1F TVZVVHVCQHZYKX-UHFFFAOYSA-N 0.000 description 4
- UICDWYMPSULFDH-UHFFFAOYSA-N n-[3-(5-cyano-4-methoxy-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OC)C(C#N)=CN=C3NC=2)=C1F UICDWYMPSULFDH-UHFFFAOYSA-N 0.000 description 4
- VYFDBKAXHKRZOC-UHFFFAOYSA-N n-[3-[4-[(1-ethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound C1=NN(CC)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C(=CC=CC=3)F)C=CC=1F)F)=CN2 VYFDBKAXHKRZOC-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- FRZNJFWQVYAVCE-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)phenyl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=CC(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 FRZNJFWQVYAVCE-UHFFFAOYSA-N 0.000 description 3
- AFFPZJFLSDVZBV-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C(F)(F)F AFFPZJFLSDVZBV-UHFFFAOYSA-N 0.000 description 3
- LJSUCGUEQNGXDV-UHFFFAOYSA-N 3-(difluoromethoxy)-n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(OC(F)F)=C1 LJSUCGUEQNGXDV-UHFFFAOYSA-N 0.000 description 3
- IKFCURKZYDRJSJ-UHFFFAOYSA-N 4-(difluoromethoxy)-n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(OC(F)F)C=C1 IKFCURKZYDRJSJ-UHFFFAOYSA-N 0.000 description 3
- TVHXQQJDMHKGGK-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 TVHXQQJDMHKGGK-UHFFFAOYSA-N 0.000 description 3
- UFBYZQFKWVEBNH-UHFFFAOYSA-N 4-cyano-n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C#N)C=C1 UFBYZQFKWVEBNH-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- OZGGULWNRIVGNN-UHFFFAOYSA-N methyl 4-[[5-[2,6-difluoro-3-(propylsulfonylamino)benzoyl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]benzoate Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(=CC=4)C(=O)OC)N=CN=C3NC=2)=C1F OZGGULWNRIVGNN-UHFFFAOYSA-N 0.000 description 3
- QCGMRSFQUUNFNX-UHFFFAOYSA-N n'-(4-hydroxy-4-methylpentan-2-yl)benzohydrazide Chemical compound CC(O)(C)CC(C)NNC(=O)C1=CC=CC=C1 QCGMRSFQUUNFNX-UHFFFAOYSA-N 0.000 description 3
- XFKOWTJQIZCEEL-UHFFFAOYSA-N n-(3-hydroxypropyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCCO XFKOWTJQIZCEEL-UHFFFAOYSA-N 0.000 description 3
- HBGCFKROLFMUHP-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(1h-indazol-5-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C5C=NNC5=CC=4)N=CN=C3NC=2)=C1F HBGCFKROLFMUHP-UHFFFAOYSA-N 0.000 description 3
- YEBLGXSHODLILH-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(1h-indazol-6-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C5NN=CC5=CC=4)N=CN=C3NC=2)=C1F YEBLGXSHODLILH-UHFFFAOYSA-N 0.000 description 3
- SGYXPGVFWUKSJR-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-fluoro-4-methoxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C(=CC(OC)=CC=4)F)N=CN=C3NC=2)=C1F SGYXPGVFWUKSJR-UHFFFAOYSA-N 0.000 description 3
- MEMGUPIYDSXMOQ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methoxyethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCCOC)N=CN=C3NC=2)=C1F MEMGUPIYDSXMOQ-UHFFFAOYSA-N 0.000 description 3
- SMPOKUZDTFFQQE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methylpropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC(C)C)N=CN=C3NC=2)=C1F SMPOKUZDTFFQQE-UHFFFAOYSA-N 0.000 description 3
- GGDDDHNSVOHNGQ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-fluoroanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(F)C=CC=4)N=CN=C3NC=2)=C1F GGDDDHNSVOHNGQ-UHFFFAOYSA-N 0.000 description 3
- OZJHOYMQDZIBSE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methoxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(OC)C=CC=4)N=CN=C3NC=2)=C1F OZJHOYMQDZIBSE-UHFFFAOYSA-N 0.000 description 3
- AHMDJSDEUQZTNJ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methylanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,5-difluorobenzenesulfonamide Chemical compound CC1=CC=CC(NC=2C=3C(C(=O)C=4C(=C(NS(=O)(=O)C=5C(=CC=C(F)C=5)F)C=CC=4F)F)=CNC=3N=CN=2)=C1 AHMDJSDEUQZTNJ-UHFFFAOYSA-N 0.000 description 3
- RAOSKIWQEUARHS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methylanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-fluorobenzenesulfonamide Chemical compound CC1=CC=CC(NC=2C=3C(C(=O)C=4C(=C(NS(=O)(=O)C=5C(=CC=CC=5)F)C=CC=4F)F)=CNC=3N=CN=2)=C1 RAOSKIWQEUARHS-UHFFFAOYSA-N 0.000 description 3
- KRPYZHIPWNXZCB-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-methylanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(C)C=CC=4)N=CN=C3NC=2)=C1F KRPYZHIPWNXZCB-UHFFFAOYSA-N 0.000 description 3
- YQNOFXGDJWUFHW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(4-fluoroanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(F)=CC=4)N=CN=C3NC=2)=C1F YQNOFXGDJWUFHW-UHFFFAOYSA-N 0.000 description 3
- XAXSJDLGZLGMPW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(4-hydroxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(O)=CC=4)N=CN=C3NC=2)=C1F XAXSJDLGZLGMPW-UHFFFAOYSA-N 0.000 description 3
- NUTUDUFRXXTDRX-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(4-methylanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(C)=CC=4)N=CN=C3NC=2)=C1F NUTUDUFRXXTDRX-UHFFFAOYSA-N 0.000 description 3
- GUSSHXMIOQVENS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(naphthalen-1-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C5=CC=CC=C5C=CC=4)N=CN=C3NC=2)=C1F GUSSHXMIOQVENS-UHFFFAOYSA-N 0.000 description 3
- ZYOJGISTNOVNFS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxan-4-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCOCC4)N=CN=C3NC=2)=C1F ZYOJGISTNOVNFS-UHFFFAOYSA-N 0.000 description 3
- BSHUHAFBYKSEQW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C=1C=NN(C)C=1 BSHUHAFBYKSEQW-UHFFFAOYSA-N 0.000 description 3
- QIGHVCXAKZFWQB-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F QIGHVCXAKZFWQB-UHFFFAOYSA-N 0.000 description 3
- QLBLKSMYTBLZEQ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-3-fluorobenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 QLBLKSMYTBLZEQ-UHFFFAOYSA-N 0.000 description 3
- ULLYDEPBIIHVNG-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]piperidine-1-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)N1CCCCC1 ULLYDEPBIIHVNG-UHFFFAOYSA-N 0.000 description 3
- RIWUNLFLTZAADW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F RIWUNLFLTZAADW-UHFFFAOYSA-N 0.000 description 3
- FQEOBIWQCMOPHS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]pyridine-3-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CN=C1 FQEOBIWQCMOPHS-UHFFFAOYSA-N 0.000 description 3
- OOCUIBFBOOMEGY-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound C1=2C(NCCC)=NC=NC=2NC=C1C(=O)C1=C(F)C=CC(NS(=O)(=O)CCC)=C1F OOCUIBFBOOMEGY-UHFFFAOYSA-N 0.000 description 3
- CWJOXWHGAAJPPR-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4N=CC=CC=4)N=CN=C3NC=2)=C1F CWJOXWHGAAJPPR-UHFFFAOYSA-N 0.000 description 3
- ONCKQJNMIRETOG-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=NC=CC=4)N=CN=C3NC=2)=C1F ONCKQJNMIRETOG-UHFFFAOYSA-N 0.000 description 3
- KCEAZOPVIMPEKH-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(1-methylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4=CN(C)N=C4)N=CN=C3NC=2)=C1F KCEAZOPVIMPEKH-UHFFFAOYSA-N 0.000 description 3
- KYBUFINUUWYFDV-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(1-methylsulfonylpiperidin-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCN(CC4)S(C)(=O)=O)N=CN=C3NC=2)=C1F KYBUFINUUWYFDV-UHFFFAOYSA-N 0.000 description 3
- HMZSHZRYBKPNHL-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C5NC(=O)NC5=CC=4)N=CN=C3NC=2)=C1F HMZSHZRYBKPNHL-UHFFFAOYSA-N 0.000 description 3
- NMLLGXPUHUPAAD-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(3-fluoro-5-methoxypyridin-2-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C(=CC(OC)=CN=4)F)N=CN=C3NC=2)=C1F NMLLGXPUHUPAAD-UHFFFAOYSA-N 0.000 description 3
- AFQMBMAQZLLRLM-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[(6-methoxypyridin-3-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=NC(OC)=CC=4)N=CN=C3NC=2)=C1F AFQMBMAQZLLRLM-UHFFFAOYSA-N 0.000 description 3
- MJVZMVZKFFOUFA-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[3-(5-methyltetrazol-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(C=CC=4)N4C(=NN=N4)C)N=CN=C3NC=2)=C1F MJVZMVZKFFOUFA-UHFFFAOYSA-N 0.000 description 3
- NCZHZLNPTUGOQW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[3-(trifluoromethyl)anilino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(C=CC=4)C(F)(F)F)N=CN=C3NC=2)=C1F NCZHZLNPTUGOQW-UHFFFAOYSA-N 0.000 description 3
- FYLGRUZKWJANDI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[4-(trifluoromethyl)anilino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(=CC=4)C(F)(F)F)N=CN=C3NC=2)=C1F FYLGRUZKWJANDI-UHFFFAOYSA-N 0.000 description 3
- XMBKWBNBUWJCJO-UHFFFAOYSA-N n-[3-(4-anilino-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC=CC=4)N=CN=C3NC=2)=C1F XMBKWBNBUWJCJO-UHFFFAOYSA-N 0.000 description 3
- PCZJPELEZTZFDF-UHFFFAOYSA-N n-[3-(4-chloro-5-cyano-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(Cl)C(C#N)=CN=C3NC=2)=C1F PCZJPELEZTZFDF-UHFFFAOYSA-N 0.000 description 3
- JGJGDMMQDKTFCF-UHFFFAOYSA-N n-[3-(4-cyano-5-fluoro-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(C#N)C(F)=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 JGJGDMMQDKTFCF-UHFFFAOYSA-N 0.000 description 3
- GJFCDZPXZTVEQX-UHFFFAOYSA-N n-[3-(5-chloro-4-methoxy-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(OC)C(Cl)=CN=C3NC=2)=C1F GJFCDZPXZTVEQX-UHFFFAOYSA-N 0.000 description 3
- BHARVLQVABYNHC-UHFFFAOYSA-N n-[3-[4-(3-chloroanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(Cl)C=CC=4)N=CN=C3NC=2)=C1F BHARVLQVABYNHC-UHFFFAOYSA-N 0.000 description 3
- KHKNVBPZQZFMIS-UHFFFAOYSA-N n-[3-[4-(4-chloroanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(Cl)=CC=4)N=CN=C3NC=2)=C1F KHKNVBPZQZFMIS-UHFFFAOYSA-N 0.000 description 3
- WOQVFPYNIZTAMG-UHFFFAOYSA-N n-[3-[4-(benzylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC=4C=CC=CC=4)N=CN=C3NC=2)=C1F WOQVFPYNIZTAMG-UHFFFAOYSA-N 0.000 description 3
- DNPXLDGICPHHBG-UHFFFAOYSA-N n-[3-[4-(cyclopentylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCCC4)N=CN=C3NC=2)=C1F DNPXLDGICPHHBG-UHFFFAOYSA-N 0.000 description 3
- TXRJEZDBJUNDQW-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F TXRJEZDBJUNDQW-UHFFFAOYSA-N 0.000 description 3
- ZFODZEFLDPLDGO-UHFFFAOYSA-N n-[3-[4-(ethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC)N=CN=C3NC=2)=C1F ZFODZEFLDPLDGO-UHFFFAOYSA-N 0.000 description 3
- DJHVKZMVBVZTDW-UHFFFAOYSA-N n-[3-[4-[(1,3-dimethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C(=NN(C)C=4)C)N=CN=C3NC=2)=C1F DJHVKZMVBVZTDW-UHFFFAOYSA-N 0.000 description 3
- YPINHAWDYIJZOG-UHFFFAOYSA-N n-[3-[4-[(1-ethylpiperidin-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCN(CC)CC4)N=CN=C3NC=2)=C1F YPINHAWDYIJZOG-UHFFFAOYSA-N 0.000 description 3
- SDBDSUQMVGVRKH-UHFFFAOYSA-N n-[3-[4-[(1-ethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=NN(CC)C=C1NC1=NC=NC2=C1C(C(=O)C=1C(=C(NS(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C=CC=1F)F)=CN2 SDBDSUQMVGVRKH-UHFFFAOYSA-N 0.000 description 3
- PEIFASUZJCZLJF-UHFFFAOYSA-N n-[3-[4-[(1-ethylpyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4=CN(CC)N=C4)N=CN=C3NC=2)=C1F PEIFASUZJCZLJF-UHFFFAOYSA-N 0.000 description 3
- DZGRXVSBOIEZIF-UHFFFAOYSA-N n-[3-[4-[3-(dimethylamino)anilino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(C=CC=4)N(C)C)N=CN=C3NC=2)=C1F DZGRXVSBOIEZIF-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- XPXJHTLDKCRHHQ-UHFFFAOYSA-N (3-amino-2,6-difluorophenyl)-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl]methanone Chemical compound NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F XPXJHTLDKCRHHQ-UHFFFAOYSA-N 0.000 description 2
- HSPSETAYTYJKCQ-UHFFFAOYSA-N (3-amino-2,6-difluorophenyl)-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl]methanone Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C1=C(F)C=CC(N)=C1F HSPSETAYTYJKCQ-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- QAMYWGZHLCQOOJ-WRNBYXCMSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-WRNBYXCMSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- UJYSYPVQHFNBML-UHFFFAOYSA-N methyl 5-aminolevulinate hydrochloride Chemical compound [Cl-].COC(=O)CCC(=O)C[NH3+] UJYSYPVQHFNBML-UHFFFAOYSA-N 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- WGFHWGLTBMMTKT-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(2-methoxyethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCCOC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 WGFHWGLTBMMTKT-UHFFFAOYSA-N 0.000 description 2
- NFSRSXJHWQKHLB-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxan-4-ylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4CCOCC4)C=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 NFSRSXJHWQKHLB-UHFFFAOYSA-N 0.000 description 2
- OWBWEWSYFUBGDN-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxan-4-ylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCOCC4)C=CN=C3NC=2)=C1F OWBWEWSYFUBGDN-UHFFFAOYSA-N 0.000 description 2
- RMGHMMDDVZCNOW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F RMGHMMDDVZCNOW-UHFFFAOYSA-N 0.000 description 2
- QBPJPXKJEQUSKP-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCCC)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 QBPJPXKJEQUSKP-UHFFFAOYSA-N 0.000 description 2
- IOKCCXKYAWLAEA-UHFFFAOYSA-N n-[3-[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CC4)N=CN=C3NC=2)=C1F IOKCCXKYAWLAEA-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- RIWLPSIAFBLILR-WVNGMBSFSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2r,3s)-2-[[(2s)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethy Chemical compound CC(=O)N(C)CC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC RIWLPSIAFBLILR-WVNGMBSFSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DWBWMAAYLWUXQK-UHFFFAOYSA-N 2,3-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(F)=C1F DWBWMAAYLWUXQK-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- MXWHMTNPTTVWDM-UHFFFAOYSA-N 2-[1-(diaminomethylidenehydrazinylidene)propan-2-ylideneamino]guanidine Chemical compound NC(N)=NN=C(C)C=NN=C(N)N MXWHMTNPTTVWDM-UHFFFAOYSA-N 0.000 description 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- MDIUBBGSOIVWHS-UHFFFAOYSA-N 2-chloro-n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pyridine-3-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CN=C1Cl MDIUBBGSOIVWHS-UHFFFAOYSA-N 0.000 description 1
- VOJPGACLESFYOC-UHFFFAOYSA-N 2-fluoro-5-methylbenzenesulfonamide Chemical compound CC1=CC=C(F)C(S(N)(=O)=O)=C1 VOJPGACLESFYOC-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- MTVLUWDYXVZTID-UHFFFAOYSA-N 3-[[[5-[2,6-difluoro-3-(propylsulfonylamino)benzoyl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]benzoic acid Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC=4C=C(C=CC=4)C(O)=O)N=CN=C3NC=2)=C1F MTVLUWDYXVZTID-UHFFFAOYSA-N 0.000 description 1
- DXGPZFBQYZJXSA-UHFFFAOYSA-N 3-chloro-n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluorobenzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1F DXGPZFBQYZJXSA-UHFFFAOYSA-N 0.000 description 1
- UMMZXEZOHDJJFC-UHFFFAOYSA-N 3-cyano-n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(C#N)=C1 UMMZXEZOHDJJFC-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- BMMODUTUZDDWCS-UHFFFAOYSA-N 4-[[5-[2,6-difluoro-3-(propylsulfonylamino)benzoyl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]benzoic acid Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CC(=CC=4)C(O)=O)N=CN=C3NC=2)=C1F BMMODUTUZDDWCS-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QRFFTAAYSXEVOU-UHFFFAOYSA-N 4-chloro-n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluorobenzenesulfonamide Chemical compound C1=C(Cl)C(F)=CC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 QRFFTAAYSXEVOU-UHFFFAOYSA-N 0.000 description 1
- MBBBFBFUFCBJHF-UHFFFAOYSA-N 4-chloro-n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pyridine-3-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CN=CC=C1Cl MBBBFBFUFCBJHF-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 229940127124 90Y-ibritumomab tiuxetan Drugs 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 229960005500 DHA-paclitaxel Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 101150106555 Il24 gene Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100036671 Interleukin-24 Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108010072915 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt Proteins 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 1
- 102000042888 RAF family Human genes 0.000 description 1
- 108091082327 RAF family Proteins 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000007103 Spondylolisthesis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940027570 adenoviral vector vaccine Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 101150055123 afp gene Proteins 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- 229950003247 elesclomol Drugs 0.000 description 1
- BKJIXTWSNXCKJH-UHFFFAOYSA-N elesclomol Chemical compound C=1C=CC=CC=1C(=S)N(C)NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1 BKJIXTWSNXCKJH-UHFFFAOYSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- 229960000439 eribulin mesylate Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 229940039286 hepatocellular carcinoma vaccine Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229950005254 irofulven Drugs 0.000 description 1
- NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960000733 mannosulfan Drugs 0.000 description 1
- UUVIQYKKKBJYJT-ZYUZMQFOSA-N mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229950002676 menogaril Drugs 0.000 description 1
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- HZKYTXJZKGDMBO-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-hydrazinyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NN)N=CN=C3NC=2)=C1F HZKYTXJZKGDMBO-UHFFFAOYSA-N 0.000 description 1
- AVEIZAHAAQDWBF-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-iodo-5-methoxy-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(I)C(OC)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F AVEIZAHAAQDWBF-UHFFFAOYSA-N 0.000 description 1
- BNHMLDMJQKNJCU-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-morpholin-4-yl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(N4CCOCC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 BNHMLDMJQKNJCU-UHFFFAOYSA-N 0.000 description 1
- GXKKUVBNTUKHAV-UHFFFAOYSA-N n-[2,4-difluoro-3-(4-pyrrolidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(N4CCCC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 GXKKUVBNTUKHAV-UHFFFAOYSA-N 0.000 description 1
- IFUVGHDDSYQBBP-UHFFFAOYSA-N n-[2,4-difluoro-3-(5-fluoro-4-iodo-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(I)C(F)=CN=C4NC=3)C(F)=CC=2)F)=C1 IFUVGHDDSYQBBP-UHFFFAOYSA-N 0.000 description 1
- YHBKWFUOHBZPGX-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-hydroxyanilino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(O)C=CC=4)N=CN=C3NC=2)=C1F YHBKWFUOHBZPGX-UHFFFAOYSA-N 0.000 description 1
- TWMYZPBCLIZROW-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(3-pyridin-3-ylpropylamino)-7h-pyrrolo[2,3-d]pyrimidine-2-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2N=C3NC=CC3=C(NCCCC=3C=NC=CC=3)N=2)=C1F TWMYZPBCLIZROW-UHFFFAOYSA-N 0.000 description 1
- PYTWOHIZHJWAKN-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(hydroxyamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NO)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 PYTWOHIZHJWAKN-UHFFFAOYSA-N 0.000 description 1
- UAHRBSVNCKWJII-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(methylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC)N=CN=C3NC=2)=C1F UAHRBSVNCKWJII-UHFFFAOYSA-N 0.000 description 1
- IHZKGEXPPQOFRG-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(naphthalen-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C5C=CC=CC5=CC=4)N=CN=C3NC=2)=C1F IHZKGEXPPQOFRG-UHFFFAOYSA-N 0.000 description 1
- RQVTZOAVZJHMMS-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxetan-3-ylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4COC4)N=CN=C3NC=2)=C1F RQVTZOAVZJHMMS-UHFFFAOYSA-N 0.000 description 1
- QSHOBDOBIRCZOB-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxolan-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NC4COCC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 QSHOBDOBIRCZOB-UHFFFAOYSA-N 0.000 description 1
- QOOVSYASOXQRRF-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(oxolan-3-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4COCC4)N=CN=C3NC=2)=C1F QOOVSYASOXQRRF-UHFFFAOYSA-N 0.000 description 1
- VMZGIMWGLLEYRT-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-1-ethylpyrazole-4-sulfonamide Chemical compound C1=NN(CC)C=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F VMZGIMWGLLEYRT-UHFFFAOYSA-N 0.000 description 1
- ZIFPCQFYLHYXDC-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,4-difluorobenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(F)C=C1F ZIFPCQFYLHYXDC-UHFFFAOYSA-N 0.000 description 1
- UVLCIZWAJOLYQT-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-2,6-difluorobenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=C(F)C=CC=C1F UVLCIZWAJOLYQT-UHFFFAOYSA-N 0.000 description 1
- PYBFIAMCSFKRCO-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-3,5-dimethylbenzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(C)=CC(C)=C1 PYBFIAMCSFKRCO-UHFFFAOYSA-N 0.000 description 1
- VIQLPAWIRLQSOM-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-3-fluoro-4-methoxybenzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F VIQLPAWIRLQSOM-UHFFFAOYSA-N 0.000 description 1
- IYVUGTMSQZDCLC-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-6-methoxypyridine-3-sulfonamide Chemical compound C1=NC(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F IYVUGTMSQZDCLC-UHFFFAOYSA-N 0.000 description 1
- GQGXUMMPXOECHR-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]-6-methylpyridine-2-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(C)=N1 GQGXUMMPXOECHR-UHFFFAOYSA-N 0.000 description 1
- ZYWQVGCKIDCBBX-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]benzenesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=C1 ZYWQVGCKIDCBBX-UHFFFAOYSA-N 0.000 description 1
- JQPOCSRHDFXKSY-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]cyclobutanesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1CCC1 JQPOCSRHDFXKSY-UHFFFAOYSA-N 0.000 description 1
- DORQZIDKFDKWFJ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]cyclohexanesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1CCCCC1 DORQZIDKFDKWFJ-UHFFFAOYSA-N 0.000 description 1
- DDQLYEOSUGHOOR-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]cyclopentanesulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1CCCC1 DDQLYEOSUGHOOR-UHFFFAOYSA-N 0.000 description 1
- FTZBPQWZUKVRCQ-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]morpholine-4-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)N1CCOCC1 FTZBPQWZUKVRCQ-UHFFFAOYSA-N 0.000 description 1
- CRHOHRMNQQLXKO-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-2-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C1=C(F)C=CC(NS(=O)(=O)C(C)C)=C1F CRHOHRMNQQLXKO-UHFFFAOYSA-N 0.000 description 1
- MGDVCVCGQUVGRP-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC=N1 MGDVCVCGQUVGRP-UHFFFAOYSA-N 0.000 description 1
- RIAALDOZKCJADK-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]pyrrolidine-1-sulfonamide Chemical compound C1=2C(NC(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)N1CCCC1 RIAALDOZKCJADK-UHFFFAOYSA-N 0.000 description 1
- HWPRCRWTKNADMG-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridazin-4-ylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC=4C=NN=CC=4)N=CN=C3NC=2)=C1F HWPRCRWTKNADMG-UHFFFAOYSA-N 0.000 description 1
- FNGLODPRDAXIEI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-3-ylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-2-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2N=C3NC=CC3=C(NCC=3C=NC=CC=3)N=2)=C1F FNGLODPRDAXIEI-UHFFFAOYSA-N 0.000 description 1
- ICELFOSNTAAOGI-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-(pyridin-4-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=CN=CC=4)N=CN=C3NC=2)=C1F ICELFOSNTAAOGI-UHFFFAOYSA-N 0.000 description 1
- JOGHOXLBDLEIRE-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[3-(1,3-oxazol-5-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidine-2-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2N=C3NC=CC3=C(NC=3C=C(C=CC=3)C=3OC=NC=3)N=2)=C1F JOGHOXLBDLEIRE-UHFFFAOYSA-N 0.000 description 1
- PRPUGVGEEFUREK-UHFFFAOYSA-N n-[2,4-difluoro-3-[4-[3-(2-methyltetrazol-5-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC=4C=C(C=CC=4)C4=NN(C)N=N4)N=CN=C3NC=2)=C1F PRPUGVGEEFUREK-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- JCUHESGTSGIMFW-UHFFFAOYSA-N n-[2-fluoro-3-[4-(propan-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]phenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=CC(C(=O)C=2C3=C(NC(C)C)N=CN=C3NC=2)=C1F JCUHESGTSGIMFW-UHFFFAOYSA-N 0.000 description 1
- QCNDERUTIZBLCP-UHFFFAOYSA-N n-[3-(4-chloro-5-cyano-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(Cl)C(C#N)=CN=C4NC=3)C(F)=CC=2)F)=C1 QCNDERUTIZBLCP-UHFFFAOYSA-N 0.000 description 1
- PIXLAJNKGWMXMX-UHFFFAOYSA-N n-[3-(4-chloro-5-methyl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(Cl)C(C)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F PIXLAJNKGWMXMX-UHFFFAOYSA-N 0.000 description 1
- ZWWBFVDEIHZOLB-UHFFFAOYSA-N n-[3-(5-chloro-4-iodo-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(I)C(Cl)=CN=C4NC=3)C(F)=CC=2)F)=C1 ZWWBFVDEIHZOLB-UHFFFAOYSA-N 0.000 description 1
- ABGXHQGOBHCNOA-UHFFFAOYSA-N n-[3-(5-chloro-4-methyl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(C)=C(Cl)C=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 ABGXHQGOBHCNOA-UHFFFAOYSA-N 0.000 description 1
- AUMADTHLXLJCAD-UHFFFAOYSA-N n-[3-[4-(cyclopentylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CCCC4)C=CN=C3NC=2)=C1F AUMADTHLXLJCAD-UHFFFAOYSA-N 0.000 description 1
- ICHHOPUWXBCJLZ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)C=CN=C4NC=3)C(F)=CC=2)F)=C1 ICHHOPUWXBCJLZ-UHFFFAOYSA-N 0.000 description 1
- ZARXAUIVZZRSEL-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-5-(hydroxymethyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(NCC3CC3)C(CO)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F ZARXAUIVZZRSEL-UHFFFAOYSA-N 0.000 description 1
- CVWIRDYDSGTXNS-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-5-fluoro-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)C(F)=CN=C4NC=3)C(F)=CC=2)F)=C1 CVWIRDYDSGTXNS-UHFFFAOYSA-N 0.000 description 1
- USXDTLVQPPXNPH-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-5-methoxy-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(NCC3CC3)C(OC)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F USXDTLVQPPXNPH-UHFFFAOYSA-N 0.000 description 1
- WTBYWRMXLAAMFP-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-5-methyl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(NCC3CC3)C(C)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F WTBYWRMXLAAMFP-UHFFFAOYSA-N 0.000 description 1
- PREQLZCGVGZXDY-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC1=CC=C(NS(=O)(=O)C(F)(F)F)C(F)=C1C(=O)C1=CNC2=NC=NC(NCC3CC3)=C12 PREQLZCGVGZXDY-UHFFFAOYSA-N 0.000 description 1
- NZIJZLNIUWKSIG-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F NZIJZLNIUWKSIG-UHFFFAOYSA-N 0.000 description 1
- GXDKGIBSDMSEET-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,4-difluorobenzenesulfonamide Chemical compound FC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F GXDKGIBSDMSEET-UHFFFAOYSA-N 0.000 description 1
- QFYMBHXZUHZUMK-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2,6-difluorobenzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=C(F)C=CC=C1F QFYMBHXZUHZUMK-UHFFFAOYSA-N 0.000 description 1
- XFKSJIFCDROWFH-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluoro-4-methoxybenzenesulfonamide Chemical compound FC1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F XFKSJIFCDROWFH-UHFFFAOYSA-N 0.000 description 1
- GOWOAGQFEZTFMW-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluoro-4-methylbenzenesulfonamide Chemical compound FC1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F GOWOAGQFEZTFMW-UHFFFAOYSA-N 0.000 description 1
- SAPAYKGPOOPNGN-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-fluoro-5-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F SAPAYKGPOOPNGN-UHFFFAOYSA-N 0.000 description 1
- RXXYJXBQVHQQHY-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F RXXYJXBQVHQQHY-UHFFFAOYSA-N 0.000 description 1
- PYGSBAXWNOFYBE-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3,3-difluorocyclopentane-1-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCC(F)(F)C1 PYGSBAXWNOFYBE-UHFFFAOYSA-N 0.000 description 1
- XHHOIDYDMZSRHO-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3,4-difluorobenzenesulfonamide Chemical compound C1=C(F)C(F)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F XHHOIDYDMZSRHO-UHFFFAOYSA-N 0.000 description 1
- YLYSGAMTGRKUBU-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 YLYSGAMTGRKUBU-UHFFFAOYSA-N 0.000 description 1
- FHQKMLWGWQLFHA-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluoro-2-methylbenzenesulfonamide Chemical compound CC1=C(F)C=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F FHQKMLWGWQLFHA-UHFFFAOYSA-N 0.000 description 1
- DTOHEFYHFWRCEW-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluoro-4-methoxybenzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F DTOHEFYHFWRCEW-UHFFFAOYSA-N 0.000 description 1
- KFBJJYDRXLNDLZ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluoro-4-methylbenzenesulfonamide Chemical compound C1=C(F)C(C)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F KFBJJYDRXLNDLZ-UHFFFAOYSA-N 0.000 description 1
- BLXKSRYHLPTNFY-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluoro-5-(trifluoromethyl)benzenesulfonamide Chemical compound FC1=CC(C(F)(F)F)=CC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 BLXKSRYHLPTNFY-UHFFFAOYSA-N 0.000 description 1
- HPHSYWBEOAUKMG-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluorobenzenesulfonamide Chemical compound FC1=CC=CC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 HPHSYWBEOAUKMG-UHFFFAOYSA-N 0.000 description 1
- OWZTVOKWWJQHKO-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-3-fluorocyclopentane-1-sulfonamide Chemical compound C1C(F)CCC1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F OWZTVOKWWJQHKO-UHFFFAOYSA-N 0.000 description 1
- OYBJJFHQUAIBLR-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4,4-difluorocyclohexane-1-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCC(F)(F)CC1 OYBJJFHQUAIBLR-UHFFFAOYSA-N 0.000 description 1
- CMNQRXZHIRXZIW-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-fluoro-2-methylbenzenesulfonamide Chemical compound CC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F CMNQRXZHIRXZIW-UHFFFAOYSA-N 0.000 description 1
- QITMJDSJBAWQAF-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-fluorobenzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F QITMJDSJBAWQAF-UHFFFAOYSA-N 0.000 description 1
- MJJCXXYOLSTQRZ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-methylpyridine-2-sulfonamide Chemical compound CC1=CC=NC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=C1 MJJCXXYOLSTQRZ-UHFFFAOYSA-N 0.000 description 1
- ZINKZYBTDXPSEX-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-5-fluoro-2-methoxybenzenesulfonamide Chemical compound COC1=CC=C(F)C=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F ZINKZYBTDXPSEX-UHFFFAOYSA-N 0.000 description 1
- ZHTZJDRBKAJLJC-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-5-fluoro-2-methylbenzenesulfonamide Chemical compound CC1=CC=C(F)C=C1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F ZHTZJDRBKAJLJC-UHFFFAOYSA-N 0.000 description 1
- LHTRLZBRUQGJKL-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-6-fluoropyridine-2-sulfonamide Chemical compound FC1=CC=CC(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C(F)=CC=2)F)=N1 LHTRLZBRUQGJKL-UHFFFAOYSA-N 0.000 description 1
- XSDHGXQTYUNANH-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]benzenesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CC=C1 XSDHGXQTYUNANH-UHFFFAOYSA-N 0.000 description 1
- OAUAPOUZGLGHBQ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]butane-1-sulfonamide Chemical compound CCCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F OAUAPOUZGLGHBQ-UHFFFAOYSA-N 0.000 description 1
- KXIABCJRRSKGOC-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]butane-2-sulfonamide Chemical compound CCC(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F KXIABCJRRSKGOC-UHFFFAOYSA-N 0.000 description 1
- HEYFUSZTPOWOGJ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]cyclobutanesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCC1 HEYFUSZTPOWOGJ-UHFFFAOYSA-N 0.000 description 1
- XHKPUAFQQLBTGF-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]cyclohexanesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCCCC1 XHKPUAFQQLBTGF-UHFFFAOYSA-N 0.000 description 1
- ZCVOKGPKFJMECC-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]cyclopentanesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCCC1 ZCVOKGPKFJMECC-UHFFFAOYSA-N 0.000 description 1
- SIUHFCQKEVQPIQ-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]cyclopropanesulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CC1 SIUHFCQKEVQPIQ-UHFFFAOYSA-N 0.000 description 1
- NEGYQRQLOYXAMA-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F NEGYQRQLOYXAMA-UHFFFAOYSA-N 0.000 description 1
- RCYSIXBFCPDEQV-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]morpholine-4-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)N1CCOCC1 RCYSIXBFCPDEQV-UHFFFAOYSA-N 0.000 description 1
- FGXMLUWIOGBLBE-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]oxane-4-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1CCOCC1 FGXMLUWIOGBLBE-UHFFFAOYSA-N 0.000 description 1
- QOBOLXRZPDZMOD-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pentane-2-sulfonamide Chemical compound CCCC(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F QOBOLXRZPDZMOD-UHFFFAOYSA-N 0.000 description 1
- VDYCWTLCAQVACA-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-2-sulfonamide Chemical compound CC(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)=C1F VDYCWTLCAQVACA-UHFFFAOYSA-N 0.000 description 1
- XOCJNTIHLOREKL-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pyridine-2-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CC=N1 XOCJNTIHLOREKL-UHFFFAOYSA-N 0.000 description 1
- RYQLJDBYSCPDLC-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pyridine-3-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)C1=CC=CN=C1 RYQLJDBYSCPDLC-UHFFFAOYSA-N 0.000 description 1
- BHQXXOPQWOODTK-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]pyrrolidine-1-sulfonamide Chemical compound FC1=C(C(=O)C=2C3=C(NCC4CC4)N=CN=C3NC=2)C(F)=CC=C1NS(=O)(=O)N1CCCC1 BHQXXOPQWOODTK-UHFFFAOYSA-N 0.000 description 1
- NKRJLMYGCVBOPG-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2-fluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)N=CN=C4NC=3)C=CC=2)F)=C1 NKRJLMYGCVBOPG-UHFFFAOYSA-N 0.000 description 1
- YWFMUEQWANFGBD-UHFFFAOYSA-N n-[3-[4-[(1-benzylpyrrolidin-3-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=C(NC4CN(CC=5C=CC=CC=5)CC4)N=CN=C3NC=2)=C1F YWFMUEQWANFGBD-UHFFFAOYSA-N 0.000 description 1
- FNQRJMXCOPTFCQ-UHFFFAOYSA-N n-[3-[4-[2-(dimethylamino)ethylamino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluorophenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=2C(NCCN(C)C)=NC=NC=2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 FNQRJMXCOPTFCQ-UHFFFAOYSA-N 0.000 description 1
- COHLVLVGDGEBMC-UHFFFAOYSA-N n-[3-[4-chloro-5-(hydroxymethyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound C12=C(Cl)C(CO)=CN=C2NC=C1C(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC(F)=CC=C1F COHLVLVGDGEBMC-UHFFFAOYSA-N 0.000 description 1
- SZGXEDNQLSZXJS-UHFFFAOYSA-N n-[3-[5-chloro-4-(cyclopropylmethylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)C(Cl)=CN=C4NC=3)C(F)=CC=2)F)=C1 SZGXEDNQLSZXJS-UHFFFAOYSA-N 0.000 description 1
- ISDLILCSYAKTSP-UHFFFAOYSA-N n-[3-[5-cyano-4-(cyclopropylmethylamino)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-2,5-difluorobenzenesulfonamide Chemical compound FC1=CC=C(F)C(S(=O)(=O)NC=2C(=C(C(=O)C=3C4=C(NCC5CC5)C(C#N)=CN=C4NC=3)C(F)=CC=2)F)=C1 ISDLILCSYAKTSP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 125000004316 oxathiadiazolyl group Chemical group O1SNN=C1* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960004403 pixantrone Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960002812 sunitinib malate Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- FDTAUJJRHBRHIJ-FDJAAIFISA-N tpi-287 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@H](OC(C)=O)[C@@H]3OC(O[C@H]4C[C@H]5OC[C@]5([C@@H]1[C@]34C)OC(C)=O)C=C)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 FDTAUJJRHBRHIJ-FDJAAIFISA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
- 229950002860 triplatin tetranitrate Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- compounds are provided, as well as various salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof.
- compounds are of Formula I, Formula II, Formula III and Formula Ilia as described below.
- the compounds inhibit one or more Raf protein kinases, including one or more of A-Raf, B-Raf, and c-Raf-l, and any mutations thereof.
- the compounds inhibit c-Raf-l protein kinase.
- the compounds inhibit c-Raf-l protein kinase selectively to other Raf protein kinases.
- the compounds inhibit a B-Raf V600X mutant protein kinase (where X is an amino acid other than valine, e.g., alanine, arginine, aspartic acid, glycine, lysine or methionine).
- the compounds inhibit a B-Raf V600E mutant protein kinase.
- the compounds inhibit a B-Raf V600E mutant protein kinase selectively relative to other Raf protein kinases, including B-Raf protein kinase.
- the compounds inhibit each of c-Raf-l, B-Raf, B-Raf V600X, and B-Raf V600E protein kinase.
- Also contemplated in accordance with the present invention are methods for the use of the compounds in treating diseases and conditions associated with regulation of the activity of one or more Raf protein kinases, including one or more of A-Raf, B-Raf, and c-Raf-l, and any mutations thereof.
- the use of compounds for therapeutic methods involving modulation of protein kinases are provided.
- the compounds inhibit the activity on one or more Raf kinases, including A-Raf, B-Raf and/or c-Raf-l, including any mutations thereof.
- the compounds are used for therapeutic methods involving modulation of one or more Raf protein kinases, including treatment of a variety of indications, including, but not limited to, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, cholangiocarcinoma, acute pain, chronic pain and polycystic kidney disease.
- a variety of indications including, but not limited to, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, cholangiocarcinoma, acute pain, chronic pain and polycystic
- the compounds are used for therapeutic methods involving modulation of B-Raf V600E mutant protein kinase, including treatment of a variety of indications, including, but not limited to, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma.
- the compounds are used for therapeutic methods involving modulation of c-Raf-1 protein kinase, including treatment of a variety of indications, including, but not limited to, acute pain, chronic pain and polycystic kidney disease.
- Y is selected from the group consisting of fluoro, chloro, bromo, iodo, lower alkyl, lower alkoxy, haloalkyl, CN, -OH, fluoro substituted alkyl, cycloalkyl, -OR 8 , and -N(R 3 )-R 4 ;
- R 1 is selected from the group consisting of lower alkyl, haloalkyl, haloalkoxy, fluoro substituted lower alkyl, cycloalkyl optionally substituted with one or more R 7 , heterocycloalkyl,
- R 1 is 2-fluoro-substituted phenyl, 3-fluoro-substituted phenyl, 2,5-difluoro-substituted phenyl or 4-lower alkyl-substituted phenyl, wherein lower alkyl is optionally substituted with one or more fluorine), and heteroaryl optionally substituted with one or more R 7 ;
- R 2 is hydrogen, fluoro, chloro or lower alkyl optionally substituted with one or more fluorine;
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OR 8 , lower alkyl optionally substituted with one or more R 11 , cycloalkyl optionally substituted with one or more R 12 , cycloalkylalkyl optionally substituted with one or more R , heterocycloalkyl optionally substituted with one or more R 13 , heterocycloalkylalkyl optionally substituted with one or more R 13 , aryl optionally substituted with one or more R 14 , arylalkyl optionally substituted with one or more R 14 , and heteroaryl optionally substituted with one or more R 15 ;
- R 3 and R 4 are both lower alkyl
- R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino or R 3 and R 4 combine with the nitrogen atom to which they are attached to form a 3-7 membered ring having 0-1 additional heteroatom selected from O or N;
- R 5 is selected from the group consisting of hydrogen, fluoro, chloro, -CN, lower alkyl optionally substituted with one or more R 16 , and lower alkoxy optionally substituted with one or more R 17 ; each R 6 , when present, is independently selected from the group consisting of fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, -C(0)-0-R 18 , -N(H)-C(0)-R 19 , and heteroaryl optionally substituted with one or more lower alkyl; or two R 6 on adjacent carbons combine to form a fused heterocycloalkyl optionally substituted with one or more lower alkyl;
- each R 7 when present, is independently selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, lower alkoxy, -C(0)-0-R 20 , and heteroaryl optionally substituted with one or more lower alkyl;
- R 8 is hydrogen, lower alkyl optionally substituted with one or more fluorine, or, when R 8 is a C 2 -6 alkyl, said alkyl may optionally be substituted with one or more R 21 ; cycloalkyl optionally substituted with one or more R 21 , or heterocycloalkyl optionally substituted with one or more R 21 ; each R 11 , when present, is independently selected from the group consisting of fluoro, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino,
- each R 12 when present, is independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono- alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, -N(H)-C(0)-R 22 ,
- each R 13 when present, is independently selected from the group consisting of fluoro, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, -N(H)-C(0)-R , -N(H)-S(0) 2 -R , C(0)-R , S(0)2-R 29 , and lower alkyl optionally substituted with one or more R 30 ;
- each R 14 and R 15 when present, are independently selected from the group consisting of fluoro, chloro, -OH, -NH 2 , -CN, -N0 2 , -N(H)-C(0)-R 31 , -N(H)-S(0) 2 -R 32 , C(0)-R 33 , S(0) 2 -R 34 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono- alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, aryl optionally substituted with one or more R 35 , and heteroaryl optionally substituted with one or more R 36 ;
- each R 16 when present, is independently fluoro, -OH, lower alkoxy, -NH 2 , mono-alkylamino, di- alkylamino, cycloalkylamino, or heterocycloalkylamino;
- each R 17 when present, is independently fluoro, -OH, lower alkoxy, -NH 2 , mono-alkylamino, di- alkylamino, cycloalkylamino, or heterocycloalkylamino;
- each R 18 and R 20 when present, are independently hydrogen, lower alkyl or fluoro substituted lower alkyl;
- each R , R , R , R , R , R and R when present, are independently lower alkyl or fluoro
- each R 21 when present, is fluoro, -OH, lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino;
- each R 24 , R 25 , R 28 , R 29 , R 33 , and R 34 when present, are independently lower alkyl, fluoro substuted lower alkyl, -OH, lower alkoxy, fluor substituted lower alkoxy, -NH 2 , mono-alkylamino, di- alkylamino, cycloalkylamino, or heterocycloalkylamino;
- each R 30 when present, is independently fluoro, aryl optionally substituted with one or more R 35 or heteroaryl optionally substituted with one or more R 36 ;
- each R 35 and R 36 when present, are independently selected from the group consisting of fluoro, chloro, -OH, -NH 2 , -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and
- Y is selected from the group consisting of fluoro, chloro, bromo, iodo, lower alkyl, lower alkoxy, haloalkyl (e.g., fluoro substituted alkyl), CN, -OH, cycloalkyl, -OR 8 , and -N(R 3 )-R 4 ;
- R 1 is selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, cycloalkyl, mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, phenyl optionally substituted with from one to three R 6 (e.g., R 1 is 2-fluoro-substituted phenyl, 3-fluoro-substituted phenyl, 2,5-difluoro-substituted phenyl or 4-lower alkyl-substituted phenyl, wherein lower alkyl is optionally substituted with from one to three fluorine atoms), and heteroaryl optionally substituted with one to three R 7 ;
- R 2 is hydrogen, fluoro, chloro, or lower alkyl optionally substituted with one or more fluorine;
- R 3 is hydrogen and R 4 is selected from the group consisting of (i) hydrogen, -OR 8 and lower alkyl optionally substituted with from one to three R 11 ; (ii) cycloalkyl or cycloalkylalkyl, each of which is optionally substituted with from one to three R 12 ; (iii) heterocycloalkyl or
- heterocycloalkylalkyl each of which is optionally substituted with from one to three R 13 ;
- aryl or arylalkyl each of which is optionally substituted with from one to three R 14 optionally, wherein the two adjacent R 14 groups on the aryl ring are taken together to form a 5 or 6- membered hetero aromatic ring having from 1 -4 heteroatoms selected from O or N; and
- R 3 and R 4 combine with the nitrogen atom to which they are attached to form a three to seven membered ring having 0-1 additional heteroatom selected from O, N or S, wherein the nitrogen and sulfur atoms are optionally oxidized;
- each R 6 when present, is independently selected from the group consisting of fluoro, chloro, -CN, -NO 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, -C(0)-0-R 18 , -N(H)-C(0)-R 19 , and heteroaryl optionally substituted with one or more lower alkyl; or two R 6 on adjacent carbons combine to form a fused heterocycloalkyl optionally substituted with one or more lower alkyl;
- each R 7 when present, is independently selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, lower alkoxy, -C(0)-0-R 20 , and heteroaryl optionally substituted with one or more lower alkyl;
- R 11 when present, is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono- alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino; each R and R , when present, are independently selected from the group consisting of fluoro, chloro, -CN, -NO 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy;
- each R 18 when present, is independently hydrogen or lower alkyl
- each R 19 when present, is independently lower alkyl
- each R 20 when present, is independently hydrogen or lower alkyl.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- R 1 is lower alkyl or cycloalkyl (e.g., cyclopropyl), preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like; and
- R 2 is hydrogen.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i- propyl, sec-butyl, i-butyl, and the like; and
- R 2 is fluoro. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec- butyl, i-butyl, and the like.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like
- R 2 is hydrogen.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like
- R 2 is fluoro. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -OR 8 ;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec- butyl, i-butyl, and the like
- R 8 is hydrogen, lower alkyl optionally substituted with one or more fluorine, or cycloalkyl optionally substituted with one or more fluorine.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like, and R 8 is hydrogen, lower alkyl optionally substituted with one or more fluorine, or cycloalkyl optionally substituted with one or more fluorine; and R 2 is hydrogen.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like, and R 8 is hydrogen or lower alkyl ; and R 2 is fluoro. All the other variables are as defined in any of the above embodiments, or as described hereinafter.
- Y is -N(R 3 )-R 4 ;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and
- R 2 is hydrogen.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and R 2 is fluoro.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec- butyl, i-butyl, and the like
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form a three to seven membered ring having 0-1 additional heteroatom selected from O, N or S, wherein the nitrogen and sulfur atoms are optionally oxidized
- R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cyclol,
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 2 is fluoro.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl; R 1 is mono-alkylamino, di-alkylamino,
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino ; and R 2 is fluoro. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino.
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino; and
- R 2 is fluoro.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -N(R 3 )-R 4 ; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino. In some embodiments of compounds of Formula I, Y is -N(R 3 )-R 4 ; R 1 is mono-alkylamino,
- Y is -N(R 3 )-R 4 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino ; and
- R 2 is fluoro.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylammo, preferably di-alkylamino or cycloalkylamino
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkylamino,
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is hydrogen.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R 2 is hydrogen
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy, and R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -N(R 3 )-R 4 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- Y is -N(R 3 )-R 4 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is hydrogen.
- R 1 is phenyl mono- substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy; and R 2 is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alky
- R 13 is selected from the group consisting of fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl,
- heterocycloalkyl optionally substituted with lower alkyl
- phenyl optionally substituted with one or more R 14
- 5-6 membered heteroaryl optionally substituted with one or more lower alkyl
- R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form
- cycloalkylamino wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino, and R 14 is selected from the group consisting of fluoro, chloro, -CN, -NO 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di- substituted with methoxy.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the above embodiments or as described hereinafter.
- Y is -N(R 3 )-R 4 ; R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is -N(R 3 )-R 4 ; R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and R 2 is hydrogen.
- Y is -N(R 3 )-R 4 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di- substituted with methoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkyla
- R 37 is selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, cycloalkyl, mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, phenyl optionally substituted with one or more R (e.g., R is 2-fluoro-substituted phenyl, 3-fluoro-substituted phenyl, 2,5-difluoro-substituted phenyl or 4-lower alkyl-substituted phenyl, wherein lower alkyl is optionally substituted with one or more fluorine), and heteroaryl optionally substituted with one or more R 42 ;
- R 38 is hydrogen, fluoro, chloro, or lower alkyl optionally substituted with one or more fluorine;
- R 39 and R 40 are independently selected from the group consisting of fluoro, chloro, -CN, -OH, -NH 2 , lower alkyl optionally substituted with one or more R 43 , lower alkenyl optionally substituted with C(0)-0-R 44 , lower alkynyl optionally substituted with lower alkyl optionally substituted with one or more fluorine, or, on a non-alkynyl carbon thereof, R 45 , lower alkoxy optionally substituted with R 46 , mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino;
- each R 41 when present, is independently selected from the group consisting of fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, -C(0)-0-R 47 , -N(H)-C(0)-R 48 , and heteroaryl optionally substituted with one or more lower alkyl; or two R 41 on adjacent carbons combine to form a fused heterocycloalkyl optionally substituted with one or more lower alkyl;
- each R 42 when present, is independently selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, -C(0)-0-R 49 , and heteroaryl optionally substituted with one or more lower alkyl;
- each R 43 when present, is independently selected from the group consisting of fluoro, -OH, lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino;
- each R 44 when present, is independently hydrogen or lower alkyl optionally substituted with one or more fluorine;
- each R 45 when present, is independently selected from the group consisting of -OH, lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino;
- each R 46 when present, is independently selected from the group consisting of -OH, lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino;
- each R 47 when present, is independently hydrogen or lower alkyl optionally substituted with one or more fluorine;
- each R 48 when present, is independently lower alkyl optionally substituted with one or more fluorine;
- each R 49 when present, is independently hydrogen or lower alkyl optionally substituted with one or more fluorine.
- R is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like.
- R 37 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy.
- R 37 is lower alkyl, fluoro substituted lower alkyl or phenyl, optionally substituted with from 1 -3 R 41 groups.
- R 37 is lower alkyl, fluoro substituted lower alkyl or phenyl substituted with from 1-3 groups selected from fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy,
- R 37 is lower alkyl or phenyl substituted with from 1 -2 groups selected from fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy or fluoro substituted lower alkoxy.
- R 37 is lower alkyl or phenyl optionally substituted with 1 -2 members selected from CF 3 or halogen. In other embodiments, R 37 is propyl.
- R 37 is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4- trifluoromethylphenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl or 2,5-difluoro-substituted phenyl. All the other variables are as defined in any of the embodiments of the compounds of Formula II described herein.
- R 37 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- R 37 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy.
- R 37 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 38 is hydrogen.
- R 37 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 38 is fluoro. All the other variables are as defined in any of the embodiments of the compounds of Formula II described herein.
- R 37 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- R 37 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy.
- R 37 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di- substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy. In some embodiments, R 37 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy, R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy, and R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy.
- R 37 is phenyl mono- substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 38 is hydrogen.
- R 37 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 38 is fluoro.
- R 37 is 4- trifluoromethylphenyl, 2-fluorophenyl, 3 -fluorophenyl or 2,5-difluoro-substituted phenyl. All the other variables are as defined in any of the embodiments of the compounds of Formula II described herein.
- R 37 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- R 37 is 5- 6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy.
- R 37 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy, R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy, and R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy; and R 38 is hydrogen. In some embodiments, R 37 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents
- R 39 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 40 is fluoro, chloro, -CN, lower alkyl, or lower alkoxy
- R 38 is fluoro.
- R 38 is H, -F or fluoro substituted lower alkyl.
- R 38 is H, F or CF 3 .
- R 38 is F.
- R 39 is fluoro, chloro, -CN, -OH, -NH 2 , lower alkoxy, lower alkyl optionally substituted with one or more R 43 , cycloalkylamino, cycloalkylalkyl- ⁇ -, heterocycloalkylamino and heterocycloalkylalkyl-NH-.
- R 39 is fluoro, chloro, -CN, -OH, -NH 2 , lower alkyl optionally substituted with fluoro, lower alkoxy, cycloalkylamino, cycloalkylalkyl-NH-, heterocycloalkylamino and heterocycloalkylalkyl-NH-.
- R 39 is fluoro, chloro, -CN, -OH, -NH 2 , CH 3 , CH 3 O-, CF 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cyclopropylmethylammo, cyclobutylmethylammo, cyclopentylmethylammo, cyclohexylmethylammo, 2- tetrahydrofuranylamino, 3-tetrahydrofuranylamino or 4-tetrahydropyranylamino. All the other variables are as defined in any of the embodiments of the compounds of Formula II described herein.
- R 40 is H, lower alkyl optionally substituted with one or more R 43 , halogen, lower alkoxy or -CN.
- R 43 is fluoro, -OH, lower alkoxy, mono-alkylamino, di-alkylamino, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, 2-tetrahydrofuranylamino, 3-tetrahydrofuranylamino, 2- tetrahydropyranylamino, 3-tetrahydropyranylamino or 4-tetrahydropyranylamino. All the other variables are as defined in any of the embodiments of the compounds of Formula II described herein.
- Y is selected from the group consisting of fluoro, chloro, bromo, iodo, lower alkyl, lower alkoxy, haloalkyl, CN, -OH, fluoro substituted alkyl, cycloalkyl, -OR 8 , and -N(R 3 )-R 4 ;
- R 1 is selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, cycloalkyl, mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, phenyl optionally substituted with one or more R 6 (e.g., R 1 is 2-fluoro-substituted phenyl, 3-fluoro-substituted phenyl, 2,5-difluoro-substituted phenyl or 4-lower alkyl-substituted phenyl, wherein lower alkyl is optionally substituted with one or more fluorine), and heteroaryl optionally substituted with one or more R 7 ;
- R 2 is hydrogen, fluoro, chloro, or lower alkyl optionally substituted with one or more fluorine;
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OR 8 , lower alkyl optionally substituted with one or more R 11 , cycloalkyl optionally substituted with one or more R 12 , heterocycloalkyl optionally substituted with one or more R 13 , aryl optionally substituted with one or more R 14 , and heteroaryl optionally substituted with one or more R 15 ;
- R 3 and R 4 are both lower alkyl
- R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino
- each R 6 when present, is independently selected from the group consisting of fluoro, chloro, -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, -C(0)-0-R 18 , -N(H)-C(0)-R 19 , and heteroaryl optionally substituted with one or more lower alkyl; or two R 6 on adjacent carbons combine to form a fused heterocycloalkyl optionally substituted with one or more lower alkyl;
- each R 7 when present, is independently selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, lower alkoxy, -C(0)-0-R 20 , and heteroaryl optionally substituted with one or more lower alkyl;
- R 8 is hydrogen, lower alkyl optionally substituted with one or more fluorine, or, when R 8 is a C 2 _6 alkyl, said alkyl may optionally be substituted with one or more R 21 ; cycloalkyl optionally substituted with one or more R 21 , or heterocycloalkyl optionally substituted with one or more R 21 ; each R 11 , when present, is independently selected from the group consisting of fluoro, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino,
- each R 12 when present, is independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono- alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, -N(H)-C(0)-R 22 ,
- each R 13 when present, is independently selected from the group consisting of fluoro, -OH, lower alkoxy, fluoro substituted lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino,
- each R and R when present, are independently selected from the group consisting of fluoro, chloro, -OH, -NH 2 , -CN, -N0 2 , -N(H)-C(0)-R 31 , -N(H)-S(0) 2 -R 32 , C(0)-R 33 , S(0) 2 -R 34 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono- alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, aryl optionally substituted with one or more R 35 , and heteroaryl optionally substituted with one or more R 36 ;
- each R 17 when present, is independently fluoro, -OH, lower alkoxy, -NH 2 , mono-alkylamino, di- alkylamino, cycloalkylamino, or heterocycloalkylamino;
- each R 18 and R 20 when present, are independently hydrogen, lower alkyl or fluoro substituted lower alkyl;
- each R , R , R , R , R , R and R when present, are independently lower alkyl, fluoro
- each R 21 when present, is fluoro, -OH, lower alkoxy, -NH 2 , mono-alkylamino, di-alkylamino,
- each R 24 , R 25 , R 28 , R 29 , R 33 , and R 34 when present, are independently lower alkyl, fluoro substuted lower alkyl, -OH, lower alkoxy, fluor substituted lower alkoxy, -NH 2 , mono-alkylamino, di- alkylamino, cycloalkylamino, , or heterocycloalkylamino;
- each R 30 when present, is independently fluoro, aryl optionally substituted with one or more R 35 or heteroaryl optionally substituted with one or more R 36 ;
- each R 35 and R 36 when present, are independently selected from the group consisting of fluoro, chloro, -OH, -NH 2 , -CN, -N0 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl , i-propyl, sec -butyl, i-butyl, and the like; and
- R 2 is hydrogen.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl , i-propyl, sec-butyl, i-butyl, and the like; and
- R 2 is fluoro.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and
- R 2 is hydrogen.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like
- R 2 is fluoro.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is -OR 8 ;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- Y is -OR 8 ;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and
- R 2 is fluoro.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec- butyl, i-butyl, and the like
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec -butyl, i-butyl, and the like.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and R 2 is hydrogen.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec-butyl, i-butyl, and the like; and R 2 is fluoro.
- R 1 is lower alkyl or cycloalkyl, preferably lower alkyl, preferably n-propyl, i-propyl, sec- butyl, i-butyl, and the like
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkylamino,
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro; R 1 is mono-alkylamino, di-alkylamino,
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino; and
- R 2 is fluoro.
- R 1 is
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- R 1 is mono-alkylamino, di-alkylamino,
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 2 is fluoro.
- R 1 is
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino.
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino; and
- R 2 is fluoro.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is-N(R 3 )-R 4 ; R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino. In some embodiments of compounds of Formula III, Y is-N(R 3 )-R 4 ; R 1 is mono-alkylamino,
- Y is-N(R 3 )-R 4 ;
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino; and
- R 2 is fluoro.
- R 1 is mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino, preferably di-alkylamino or cycloalkylamino
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkylamino
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro; R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro; R 1 is phenyl optionally substituted with 1 or 2 substituents
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and R is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R 2 is hydrogen
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- Y is -OR 8 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is hydrogen.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy; and R 2 is fluoro.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is -N(R 3 )-R 4 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy.
- Y is -N(R 3 )-R 4 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is hydrogen.
- Y is -N(R 3 )-R 4 ;
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and
- R 2 is fluoro.
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di-substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy.
- R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alky
- R 1 is phenyl mono-substituted with fluoro, lower alkyl, or -CF 3 , or di- substitited with two fluoro, two lower alkyl, or one fluoro and one lower alkoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R 3 and R 4 are both lower alkyl, or R 3 and R 4 combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is fluoro, chloro, bromo, or iodo, preferably fluoro;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di- substituted with methoxy.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is lower alkyl, fluoro substituted alkyl, or cycloalkyl;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy. All the other variables are as defined in any of the embodiments of the compounds of Formulasl, II and III described herein.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is hydrogen.
- Y is -OR 8 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy
- R 8 is hydrogen or lower alkyl. All the other variables are as defined in any of the embodiments of the compounds of Formulas I, II and III described herein.
- Y is -N(R 3 )-R 4 ; R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy.
- Y is -N(R 3 )-R 4 ; R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and R 2 is hydrogen.
- Y is -N(R 3 )-R 4 ;
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di-substituted with methoxy; and
- R 2 is fluoro.
- R 1 is 5-6 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of lower alkyl and lower alkoxy, preferably pyrdinyl mono- or di- substituted with methoxy
- R 3 is hydrogen and R 4 is selected from the group consisting of hydrogen, -OH, lower alkyl optionally substituted with R 11 , cycloalkyl, heterocycloalkyl optionally substituted with lower alkyl, phenyl optionally substituted with one or more R 14 , and 5-6 membered heteroaryl optionally substituted with one or more lower alkyl, or R and R are both lower alkyl, or R and R combine with the nitrogen to which they are attached to form cycloalkylamino, wherein R 11 and R 14 are as defined for Formula I, preferably wherein R 11 is selected from the group consisting of cycloalkyl, -OH, lower alkoxy, mono-alkylamino, di-alkylamino,
- Y is fluoro, chloro, bromo, iodo, lower alkyl, lower alkoxy, haloalkyl, CN, -OH, cycloalkyl, -OR 8 or -NH(R 4 ).
- Y is CH 3 , ethyl, methoxy, ethyoxy, isobutyl, CN, OH, F, CI, Br, I, NH 2 , butyoxy, 2-methylpropoxy, 4- tetrahydropyranyloxy, 2-tetrahyrofuranyloxy, 3-tetrahyrofuranyloxy, alkoxyamino or HO-NH-.
- the invention provides a compound having subformula Ilia:
- Y 1 is lower alkyl optionally substituted with from one to three R 11 , cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, wherein:
- cycloalkyl and cycloalkylalkyl are each optionally substituted with from one to three R 12 ;
- the heterocycloalkyl and heterocycloalkylalkyl are each optionally substituted with from one to three R 13 ; the aryl and arylalkyl are each optionally substituted with from one to three R 14 optionally, wherein the two adjacent R 14 groups on the aryl ring are taken together to form a 5 or 6-membered hetero aromatic ring having from 1-4 heteroatoms selected from O or N; and the heteroaryl and heteroarylalkyl are each optionally substituted with from one to three R 15 .
- the other variables R 1 and R 2 are as defined in any of the embodiments of compounds of Formulas I, II and III described herein.
- Y 1 is selected from lower alkyl, halogen substituted lower alkyl, 2-hydroxyethyl, cyclopropylamino, cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexyl, 2-oxetanyl, 2- oxetanylmethyl, 3-oxetanyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrofuranylmethyl, 3- tetrahydrofuranylmethyl, 2-tetrahydropyranylmethyl, 3-tetrahydropyranylmethyl, 4- tetrahydropyranylmethyl, 1 -
- R 2 is H or F.
- the other variables R 1 and Y 1 are as defined in any of the embodiments of compounds of Formulas I, II, III and Ilia described herein.
- R 1 is lower alkyl, cycloalkyl optionally substituted with 1 -2 groups selected from halogen or lower alkyl, heterocycloalkyl, heteroaryl optionally substituted with lower alkyl or lower alkoxy, phenyl optionally substituted with 1 -2 substitutents selected from lower alkyl, halogen, lower alkoxy, haloalkyl, haloalkoxy or CN.
- R 1 is methyl, propyl, isobutyl, 2-methylpropyl, CF 3 , CF 3 CH 2 -, CHF 2 CH 2 -, 4- trifluorophenyl, 2-trifluorophenyl, 3-trifluorophenyl, 3,5-dimethylphenyl, 4-propylphenyl, 3-fluoro-4- methoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-fluoro-3-methoxyphenyl, 2,5- difluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 2-pyridyl, 3-pyridyl, 5-methoxy-2-pyridyl, 3- methoxy-2-pyridyl, 4-methoxy-2-pyridyl, 6-methyl -2-pyridyl, 5-methyl -2-pyridyl, 4-methyl -2-pyridyl, 6-methyl
- R 1 is 2-fluorophenyl, 3 -fluorophenyl, 2,5-difluorophenyl or 4-lower alkyl-substituted phenyl, wherein lower alkyl is optionally substituted with one or more fluorine. All the other variables are as defined in any of the embodiments of compounds of Formulas I, II, III and Ilia described herein.
- Y is -NR 3 R 4 , wherein R 3 and R 4 combine with the nitrogen atom to which they are attached to form a three to seven membered ring having 0-1 additional ring heteroatom selected from O, N or S, wherein the nitrogen or sulfur atom is optionally oxidized.
- Y is 1 -aziridinyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1 - piperidinyl, 1 -morpholinyl or 1 -azepanyl. All the other variables are as defined in any of the
- the compound is selected from the group consisting of:
- Morpholine-4-sulfonic acid [2,4-difluoro-3-(4-isopropylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)- phenyl] -amide (P-l 129),
- Morpholine-4-sulfonic acid ⁇ 3-[4-(cyclopropylmethyl-amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]- 2,4-difluoro-phenyl ⁇ -amide (P-1218),
- Butane- 1 -sulfonic acid ⁇ 3-[4-(cyclopropylmethyl-amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4- difluoro-phenyl ⁇ -amide (P-1224),
- Pentane -2-sulfonic acid ⁇ 3-[4-(cyclopropylmethyl-amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4- difluoro-phenyl ⁇ -amide (P-1225), N- ⁇ 3-[4-(Cyclopropylmethyl-amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2,4-difluoro-phenyl ⁇ - C,C,C-trifluoro-methanesulfonamide (P-1226),
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- any salt, prodrug, tautomer, or stereoisomer thereof any salt, prodrug, tautomer, or stereoisomer thereof.
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of: N-[2,4-Difluoro-3-(4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-trifluoromethyl- benzenesulfonamide (P-1001),
- the compound is selected from the group consisting of: N-[2,4-Difluoro-3-(4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-trifluoromethyl- benzenesulfonamide (P-1001),
- the compound is selected from the group consisting of: N-[2,4-Difluoro-3-(4-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-isopropyl- benzenesulfonamide (P-1009),
- the compound is selected from the group consisting of: Propane- 1 -sulfonic acid [2,4-difluoro-3-(4-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]- amide (P-1022),
- the compound includes any prodrug thereof.
- the compound includes any tautomer thereof.
- the compound includes any stereoisomer thereof.
- the compound includes any pharmaceutically acceptable formulation thereof.
- the compound includes any conjugate thereof.
- the compound includes any derivative thereof.
- the compound includes any form thereof.
- a compound or group of compounds includes salts of such compound(s) (including pharmaceutically acceptable salts), formulations of such compound(s) (including pharmaceutically acceptable formulations), conjugates thereof, derivatives thereof, forms thereof, prodrugs thereof, and all stereoisomers thereof.
- a compound as described herein includes compounds of Formula I including all sub-embodiments thereof, compounds of Formula II including all sub-embodiments thereof, and compounds as listed in the third aspect above, including all sub-embodiments thereof.
- methods for treating any Raf protein kinase mediated disease or condition in an animal subject in need thereof, wherein the method involves administering to the subject an effective amount of any one or more compound(s) as described herein. In certain embodiments, the method involves administering to the subject an effective amount of any one or more compound(s) as described herein in combination with one or more other therapies for the disease or condition.
- methods are provided for treating any B-Raf protein kinase mediated disease or condition, including any B-Raf mutant kinase mediated disease or condition in an animal subject in need thereof, wherein the method involves administering to the subject an effective amount of any one or more compound(s) as described herein. In certain embodiments, the method involves administering to the subject an effective amount of any one or more compound(s) as described herein in combination with one or more other therapies for the disease or condition.
- methods for treating any B-Raf V600E mutant protein kinase mediated disease or condition in an animal subject in need thereof, wherein the method involves administering to the subject an effective amount of any one or more compound(s) as described herein. In certain embodiments, the method involves administering to the subject an effective amount of any one or more compound(s) as described herein in combination with one or more other therapies for the disease or condition.
- methods are provided for treating any c-Raf-1 protein kinase mediated disease or condition, including any c-Raf-l mutant kinase mediated disease or condition in an animal subject in need thereof, wherein the method involves administering to the subject an effective amount of any one or more compound(s) as described herein. In certain embodiments, the method involves administering to the subject an effective amount of any one or more compound(s) as described herein in combination with one or more other therapies for the disease or condition.
- a compound as described herein is a Raf kinase inhibitor and has an IC 5 o of less than 500 nM, less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as determined in a generally accepted Raf kinase activity assay.
- a compound as described herein will have an IC 50 of less than 500 nM, less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM with respect to B-Raf, c-Raf-1, or B-Raf V600E mutant.
- a compound as described herein will selectively inhibit one or more Raf kinases relative to one or more other non-Raf kinases.
- a compound as described herein will selectively inhibit one Raf kinase relative to one or more other Raf kinases.
- a compound as described herein will selectively inhibit a mutation of the Raf kinase relative to the wild type kinase, for example B-Raf V600E mutant relative to wild type B-Raf.
- a compound as described herein is a B-Raf V600E inhibitor and has an IC 5 o of less than 500 nM, less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as determined in a generally accepted B-Raf V600E mutant kinase activity assay.
- the compound is selective relative to other protein kinases, such that the ratio of IC 5 o for another kinase assessed comparably, divided by the IC 5 o for B-Raf V600E mutant kinase is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100, wherein the other protein kinase includes, but is not limited to CSK, Insulin receptor kinase, AMPK, PDGFR or VEGFR.
- the compound is also selective relative to one or more other Raf kinases such that the ratio of IC 50 for another Raf kinase assessed comparably, divided by the IC 50 for B-Raf V600E mutant kinase is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100.
- a compound as described herein is a c-Raf-1 inhbitor and has an IC 50 of less than 500 nM, less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as determined in a generally accepted c-Raf-l kinase activity assay.
- IC 50 of less than 500 nM, less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as determined in a generally accepted c-Raf-l kinase activity assay.
- the compound is selective relative to other protein kinases, such that the ratio of IC 50 for another kinase assessed comparably, divided by the IC 5 o for c-Raf-1 kinase is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100, wherein the other protein kinase includes, but is not limited to CSK, Insulin receptor kinase, AMPK, PDGFR or VEGFR.
- the compound is also selective relative to one or more other Raf kinases such that the ratio of IC 5 o for another Raf kinase assessed comparably, divided by the IC50 for c-Raf-1 kinase is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100.
- the ratio of IC 5 o for another Raf kinase assessed comparably, divided by the IC50 for c-Raf-1 kinase is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100.
- a c-Raf-1 inhibitor is selective relative relative to at least B-Raf and B-Raf V600E.
- the c-Raf-1 inhibitor is a compound selected from the group consisting of:
- the c-Raf-1 inhibitor is a compound selected from the group consisting of: N-[3-(4-Cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-4- trifluoromethyl-benzenesulfonamide (P-1011),
- the c-Raf-1 inhibitor is a compound selected from the group consisting of: N-[3-(4-Cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-4- trifluoromethyl-benzenesulfonamide (P-1011),
- a compound as described herein is a pan Raf inhibitor, i.e. inhibits each of B-Raf V600E mutant kinase, B-Raf kinase and c-Raf-1 kinase, with an IC 50 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as determined in each of a generally accepted B-Raf V600E mutant kinase activity assay, B-Raf kinase activity assay, and c-Raf-1 kinase activity assay.
- the compounds are effectively equipotent on each of B-Raf V600E, B-Raf and c-Raf-1, i.e. the ratio of IC 50 for any of B-Raf V600E, B-Raf and c-Raf-1 divided by the IC 50 for any other of B-Raf V600E, B-Raf and c-Raf-1 (e.g. B-Raf IC 50 divided by B-Raf V600E IC 50 ) is in the range of 10 to 0.1, also 5 to 0.2.
- the compound is selective relative to other protein kinases, such that the ratio of IC 5 o for another kinase assessed comparably, divided by the ICso for any of B-Raf V600E, B-Raf and c-Raf-1 is >10, also >20, also >30, also >40, also >50, also >60, also >70, also >80, also >90, also >100, wherein the other protein kinase includes, but is not limited to CSK, Insulin receptor kinase, AMPK, PDGFR or VEGFR.
- the pan Raf inhibitor is a compound selected from the group consisting of:
- the pan Raf inhibitor is a compound selected from the group consisting of: Propane- 1 -sulfonic acid [3-(4-cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro- phenyl]-amide (P-1041),
- the pan Raf inhibitor is a compound selected from the group consisting of: N-[2,4-Difluoro-3-(4-propylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-trifluoromethyl- benzenesulfonamide (P-l 032),
- the pan Raf inhibitor is a compound selected from the group consisting of: Propane- 1 -sulfonic acid [3-(4-cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro- phenyl]-amide (P-1041),
- the pan Raf inhibitor is a compound selected from the group consisting of: N- ⁇ 2,4-Difluoro-3-[4-(4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl ⁇ -2,5- difluoro-benzenesulfonamide (P-1069),
- the pan Raf inhibitor is a compound selected from the group consisting of: N-[2,4-Difluoro-3-(4-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-2-fluoro- benzenesulfonamide (P-1070),
- compositions that include a therapeutically effective amount of any one or more compound(s) as described herein and at least one pharmaceutically acceptable carrier, excipient, and/or diluent, including combinations of any two or more compounds as described herein.
- the composition can further include a plurality of different pharmacologically active compounds, which can include a plurality of compounds as described herein.
- the composition can include any one or more compound(s) as described herein along with one or more compounds that are therapeutically effective for the same disease indication.
- the composition includes any one or more compound(s) as described herein along with one or more compounds that are therapeutically effective for the same disease indication, wherein the compounds have a synergistic effect on the disease indication.
- the composition includes any one or more compound(s) as described herein effective in treating a cancer and one or more other compounds that are effective in treating the same cancer, further wherein the compounds are synergistically effective in treating the cancer.
- the invention provides methods for treating a disease or condition mediated by one or more Raf kinases (including A-Raf, B-Raf, and c-Raf-1 kinases), including mutations thereof, in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein.
- the invention provides methods for treating a disease or condition mediated by one or more Raf kinases, including mutations thereof, by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.
- the invention provides methods for treating a disease or condition mediated by A-Raf kinase, including any mutations thereof, in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein.
- the invention provides methods for treating a disease or condition mediated by A-Raf kinase, including any mutations thereof, by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.
- the invention provides methods for treating a disease or condition mediated by B-Raf kinase, including any mutations thereof, in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein.
- the invention provides methods for treating a disease or condition mediated by B-Raf kinase, including any mutations thereof, by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.
- the invention provides methods for treating a disease or condition mediated by B-Raf V600E mutant kinase, in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein.
- the invention provides methods for treating a disease or condition mediated by B-Raf V600E mutant kinase, by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.
- the invention provides methods for treating a cancer mediated by B-Raf V600E mutant by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein. In one embodiment, the invention provides methods for treating a cancer mediated by B-Raf V600E mutant by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more suitable anticancer therapies, such as one or more chemotherapeutic drugs.
- the invention provides methods for treating a disease or condition mediated by c-Raf-1 kinase, including any mutations thereof, in a subject in need thereof by
- the invention provides methods for treating a disease or condition mediated by c-Raf-1 kinase, including any mutations thereof, by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.
- the invention provides a method of treating a cancer in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein.
- the invention provides a method of treating a cancer in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other therapies or medical procedures effective in treating the cancer.
- Other therapies or medical procedures include suitable anticancer therapy (e.g. drug therapy, vaccine therapy, gene therapy, photodynamic therapy) or medical procedure (e.g. surgery, radiation treatment, hyperthermia heating, bone marrow or stem cell transplant).
- the one or more suitable anticancer therapies or medical procedures is selected from treatment with a chemotherapeutic agent (e.g. chemotherapeutic drug), radiation treatment (e.g. x-ray, ⁇ -ray, or electron, proton, neutron, or a particle beam), hyperthermia heating (e.g. microwave, ultrasound, radiofrequency ablation), Vaccine therapy (e.g. AFP gene hepatocellular carcinoma vaccine, AFP adenoviral vector vaccine, AG-858, allogeneic GM-CSF-secretion breast cancer vaccine, dendritic cell peptide vaccines), gene therapy (e.g.
- a chemotherapeutic agent e.g. chemotherapeutic drug
- radiation treatment e.g. x-ray, ⁇ -ray, or electron, proton, neutron, or a particle beam
- hyperthermia heating e.g. microwave, ultrasound, radiofrequency ablation
- Vaccine therapy e.g. AFP gene hepatocellular carcinoma vaccine,
- Ad5CMV-p53 vector adenovector encoding MDA7, adenovirus 5-tumor necrosis factor alpha), photodynamic therapy (e.g. aminolevulinic acid, motexafin lutetium), surgery, or bone marrow and stem cell transplantation.
- photodynamic therapy e.g. aminolevulinic acid, motexafin lutetium
- the invention provides a pharmaceutical composition including a compound and another drug/agent, wherein the compound used in the combination includes those as described herein, for example, as defined in the claims and described in Formula I, Formula II,
- the invention further provides a method for treating a Raf protein kinase mediated disease or condition in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound and another drug or a
- the invention provides a composition for, or a method of, treating a cancer in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more suitable chemotherapeutic agents.
- the one or more suitable chemotherapeutic agents is selected from an alkylating agent, including, but not limited to, adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, tre
- PI3K inhibitors e.g. BEZ235, GDC-0941, XL147, XL765
- Cdk4 inhibitors e.g. PD-332991
- Akt inhibitors e.g. Akt inhibitors
- Hsp90 inhibitors e.g. tanespimycin
- farnesyltransferase inhibitors e.g. tipifarnib
- the method of treating a cancer involves administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with a chemotherapeutic agent selected from capecitabine, 5-fluorouracil, carboplatin, dacarbazine, gefitinib, oxaliplatin, paclitaxel, SN-38, temozolomide, vinblastine, bevacizumab, cetuximab, interferon-a, interleukin-2, or erlotinib.
- a chemotherapeutic agent selected from capecitabine, 5-fluorouracil, carboplatin, dacarbazine, gefitinib, oxaliplatin, paclitaxel, SN-38, temozolomide, vinblastine, bevacizumab, cetuximab, interferon-a, interleukin-2, or erlotinib.
- the invention provides a method of treating a disease or condition in a subject in need thereof, by administering to the subject a therapeutically effective amount of any one or more compound(s) as described herein, a prodrug of such compound, a pharmaceutically acceptable salt of such compound or prodrug, or a pharmaceutically acceptable formulation of such compound or prodrug.
- the compound can be alone or can be part of a composition.
- the invention provides a method of treating a disease or condition in a subject, by administering to the subject a therapeutically effective amount of any one or more compound(s) as described herein, a prodrug of such compound, a pharmaceutically acceptable salt of such compound or prodrug, or a pharmaceutically acceptable formulation of such compound or prodrug in combination with one or more other suitable therapies for the disease or condition.
- kits that include a compound or composition thereof as described herein.
- the compound or composition is packaged, e.g., in a vial, bottle, flask, which may be further packaged, e.g., within a box, envelope, or bag; the compound or composition is approved by the U.S.
- the compound or composition is approved for administration to a mammal, e.g., a human, for a protein kinase mediated disease or condition;
- the invention kit includes written instructions for use and/or other indication that the compound or composition is suitable or approved for administration to a mammal, e.g., a human, for a Raf protein kinase-mediated disease or condition; and the compound or composition is packaged in unit dose or single dose form, e.g., single dose pills, capsules, or the like.
- the invention provides methods for treating an A-Raf-mediated, B- Raf-mediated and/or c-Raf-1 -mediated disease or condition in a subject in need thereof (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal A-Raf, B-Raf, and/or c-Raf-1 activity (e.g. kinase activity).
- a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats
- a disease or condition characterized by abnormal A-Raf, B-Raf, and/or c-Raf-1 activity e.g. kinase activity.
- invention methods may involve administering to the subject suffering from or at risk of an A-Raf-mediated, B-Raf- mediated and/or c-Raf-1 -mediated disease or condition an effective amount of any one or more Raf inhibitor(s) as described herein.
- the A-Raf-mediated, B-Raf-mediated, and/or c-Raf- 1 -mediated disease is selected from the group consisting of neurologic diseases, including, but not limited to, multi-infarct dementia, head injury, spinal cord injury, Alzheimer's disease (AD), Parkinson's disease, seizures and epilepsy; neoplastic diseases including, but not limited to, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, carcinoma (e.g.
- lymphoma e.g.
- histiocytic lymphoma neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplasia syndrome, leukemia, tumor angiogenesis, neuroendocrine tumors such as medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, and pheochromocytoma; pain of neuropathic or inflammatory origin, including, but not limited to, acute pain, chronic pain, cancer-related pain, and migraine; cardiovascular diseases including, but not limited to, heart failure, ischemic stroke, cardiac hypertrophy, thrombosis (e.g.
- inflammation and/or proliferation including, but not limited to, psoriasis, eczema, arthritis and autoimmune diseases and conditions, osteoarthritis, endometriosis, scarring, vascular restenosis, fibrotic disorders, rheumatoid arthritis, inflammatory bowel disease (IBD); immunodeficiency diseases, including, but not limited to, organ transplant rejection, graft versus host disease, and Kaposi's sarcoma associated with HIV; renal, cystic, or prostatic diseases, including, but not limited to, diabetic nephropathy, polycystic kidney disease, nephrosclerosis, glomerulonephritis, prostate hyperplasia, polycystic liver disease, tuberous sclerosis, Von Hippel Lindau disease, medullary cystic kidney disease, nephronophthisis, and cystic fibrosis;
- metabolic disorders including, but not limited to, obesity; infection, including, but not limited to Helicobacter pylori, Hepatitis and Influenza viruses, fever, HIV, and sepsis; pulmonary diseases including, but not limited to, chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS); genetic developmental diseases, including, but not limited to, Noonan's syndrome, Costello syndrome, (faciocutaneoskeletal syndrome), LEOPARD syndrome, cardio- faciocutaneous syndrome (CFC), and neural crest syndrome abnormalities causing cardiovascular, skeletal, intestinal, skin, hair and endocrine diseases; and diseases associated with muscle regeneration or degeneration, including, but not limited to, sarcopenia, muscular dystrophies (including, but not limited to, Duchenne, Becker, Emery-Dreifuss, Limb-Girdle, Facioscapulohumeral, Myotonic, Oculopharyngeal, Distal and Congenital Muscular Dystrophies), motor neuron diseases (
- the disease or condition is selected from the group consisting of melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical cancer, prostate cancer, histiocytic lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplasia syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, acute pain, chronic pain, and polycystic kidney disease.
- the disease or condition is selected from the group consisting of melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, cholangiocarcinoma, acute pain, chronic pain, and polycystic kidney disease.
- the invention provides methods for treating a c-Raf-1 -mediated disease or condition in a subject in need thereof (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal c-Raf-1 activity (e.g. kinase activity).
- a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats
- a disease or condition characterized by abnormal c-Raf-1 activity e.g. kinase activity
- invention methods may involve administering to the subject suffering from or at risk of a c-Raf-1 -mediated disease or condition an effective amount of any one or more c-Raf-1 inhibitor(s) as described herein.
- the c-Raf-1 -mediated disease is selected from the group consisting of polycystic kidney disease, acute pain, and chronic pain.
- the invention provides methods for treating a B-Raf V600E mutant- mediated disease or condition in a subject in need thereof (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal B-Raf V600E mutant activity (e.g. kinase activity).
- a subject in need thereof e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats
- a disease or condition characterized by abnormal B-Raf V600E mutant activity e.g. kinase activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10832209.0A EP2501236B1 (en) | 2009-11-18 | 2010-11-18 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
BR112012011792A BR112012011792A2 (en) | 2009-11-18 | 2010-11-18 | "compounds and methods for modulating kinases, and indications thereof" |
ES10832209.0T ES2627911T3 (en) | 2009-11-18 | 2010-11-18 | N- [2-Fluoro-3- (4-amino-7H-pyrrolo [2,3-d] pyrimidin-5-carbonyl) -phenyl] -4-benzenesulfonamide derivatives as modulators of the Raf protein kinase for the treatment of Cancer |
CN2010800616210A CN102740698A (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
NZ599872A NZ599872A (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
RU2012125070/04A RU2012125070A (en) | 2009-11-18 | 2010-11-18 | COMPOUNDS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
MX2012005827A MX2012005827A (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor. |
AU2010321883A AU2010321883A1 (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
JP2012540066A JP2013511541A (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase regulation and indications thereof |
CA2781287A CA2781287C (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
IL219567A IL219567A0 (en) | 2009-11-18 | 2012-05-03 | Compounds and methods for kinase modulation, and indications therefor |
MA34954A MA33811B1 (en) | 2009-11-18 | 2012-06-11 | Compounds and methods used to modify kinase guidelines for this purpose |
AU2016200485A AU2016200485B2 (en) | 2009-11-18 | 2016-01-28 | Compounds and methods for kinase modulation, and indications therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26251009P | 2009-11-18 | 2009-11-18 | |
US61/262,510 | 2009-11-18 | ||
US38331010P | 2010-09-15 | 2010-09-15 | |
US61/383,310 | 2010-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011063159A1 true WO2011063159A1 (en) | 2011-05-26 |
Family
ID=44060002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/057293 WO2011063159A1 (en) | 2009-11-18 | 2010-11-18 | Compounds and methods for kinase modulation, and indications therefor |
Country Status (20)
Country | Link |
---|---|
US (2) | US8673928B2 (en) |
EP (1) | EP2501236B1 (en) |
JP (2) | JP2013511541A (en) |
KR (1) | KR20120097512A (en) |
CN (2) | CN102740698A (en) |
AU (2) | AU2010321883A1 (en) |
BR (1) | BR112012011792A2 (en) |
CA (1) | CA2781287C (en) |
CL (1) | CL2012001303A1 (en) |
CO (1) | CO6551689A2 (en) |
ES (1) | ES2627911T3 (en) |
IL (1) | IL219567A0 (en) |
MA (1) | MA33811B1 (en) |
MX (1) | MX2012005827A (en) |
MY (1) | MY156210A (en) |
NZ (1) | NZ599872A (en) |
PE (1) | PE20121335A1 (en) |
RU (1) | RU2012125070A (en) |
SG (1) | SG10201407718WA (en) |
WO (1) | WO2011063159A1 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169531A1 (en) | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
EP2672967A1 (en) * | 2011-02-07 | 2013-12-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN103626765A (en) * | 2012-08-27 | 2014-03-12 | 广东东阳光药业有限公司 | Substituted azaindole compound and salt, composition and application thereof |
WO2014048869A1 (en) * | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
WO2014048894A1 (en) * | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
WO2015017589A1 (en) * | 2013-07-31 | 2015-02-05 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
JP2015518051A (en) * | 2012-05-31 | 2015-06-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | Synthesis of pyrrolo [2,3-b] pyridine |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US9505765B2 (en) | 2012-07-26 | 2016-11-29 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN108699062A (en) * | 2015-12-23 | 2018-10-23 | 艾科尔公司 | THP trtrahydropyranyl amino-Pyrrolopyrimidine thion and its application method |
US10150783B2 (en) | 2015-01-23 | 2018-12-11 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
US10195196B2 (en) | 2012-08-13 | 2019-02-05 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US10421761B2 (en) | 2013-05-30 | 2019-09-24 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
TWI694077B (en) * | 2015-12-23 | 2020-05-21 | 美商亞闊股份有限公司 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2020239124A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
TWI750645B (en) * | 2015-12-23 | 2021-12-21 | 美商亞奎里公司 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11897889B2 (en) | 2020-08-18 | 2024-02-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
US11905292B2 (en) | 2020-08-18 | 2024-02-20 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
RU2824583C2 (en) * | 2019-05-31 | 2024-08-12 | Фочон Байосайенсиз, Лтд. | Substituted pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
RU2012125070A (en) | 2009-11-18 | 2013-12-27 | Плексксикон, Инк. | COMPOUNDS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
JP5815558B2 (en) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for kinase regulation and their indications |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AU2012255275B2 (en) | 2011-05-17 | 2016-01-28 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
CN104981247A (en) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
SI2935248T1 (en) | 2012-12-21 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PT2970265T (en) | 2013-03-15 | 2018-10-23 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6832846B2 (en) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドPlexxikon Inc. | Heterocyclic compounds and their uses |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6530826B2 (en) | 2015-05-06 | 2019-06-12 | プレキシコン インコーポレーテッドPlexxikon Inc. | Synthesis of 1H-pyrrolo [2,3-B] pyridine derivatives that modify kinases |
WO2016179415A1 (en) | 2015-05-06 | 2016-11-10 | Plexxikon Inc. | Solid forms of a compound modulating kinases |
TWI812581B (en) | 2015-05-22 | 2023-08-21 | 美商普雷辛肯公司 | Kinase modulation, and indications therefor |
BR112017024917A2 (en) | 2015-05-22 | 2018-07-31 | Plexxikon Inc | synthesis of heterocyclic compounds |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN113754656A (en) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | Heterocyclic compounds and their use |
BR112018011475A2 (en) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compounds and methods for kinase modulation and indication for kinase |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20190083460A1 (en) * | 2016-03-16 | 2019-03-21 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
CN107722013B (en) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | Deazapurine compounds, pharmaceutical compositions, preparation method and uses thereof |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
JP2018047145A (en) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | Slot machine |
JP2018047146A (en) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | Slot machine |
KR102686957B1 (en) * | 2016-11-08 | 2024-07-22 | 주식회사 대웅제약 | Novel pyrrolopyrimidine derivatives and pharmaceutical composition comprising the same |
CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
ES2896502T3 (en) | 2017-03-20 | 2022-02-24 | Plexxikon Inc | Crystal forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin acid -3- yl)benzoic that inhibit the bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
CN107298679B (en) * | 2017-06-29 | 2019-03-01 | 上海吉尔多肽有限公司 | A kind of synthetic method of chloro- 1H- pyrrolo- [2,3-B] pyridine -4- amine of 5- |
BR112019028235B1 (en) | 2017-07-25 | 2024-04-30 | Plexxikon, Inc. | COMPOSITIONS AND THEIR PREPARATION METHODS |
EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
US11103505B2 (en) | 2017-10-27 | 2021-08-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
CA3094336A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
CN108456212A (en) * | 2018-05-30 | 2018-08-28 | 杨文思 | A kind of compound or its solvate or precursor or their pharmaceutically acceptable salt, drug and application thereof |
AU2019362849A1 (en) * | 2018-10-16 | 2021-03-11 | Dana-Farber Cancer Institute, Inc. | Azaindole inhibitors of wild-type and mutant forms of LRRK2 |
EP3953351A1 (en) | 2019-04-09 | 2022-02-16 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
JP7011638B2 (en) * | 2019-12-16 | 2022-02-10 | アークル インコーポレイテッド | Tetrahydropyranylamino-pyrrolopyrimidinone and how to use it |
RU2747991C1 (en) * | 2020-02-18 | 2021-05-18 | Аркьюл, Инк. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of its use |
WO2021216898A1 (en) | 2020-04-23 | 2021-10-28 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
CN116322690A (en) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | Combination pharmaceutical anticancer therapies |
EP4234558A1 (en) * | 2020-12-07 | 2023-08-30 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | Pyrrolopyridine compound and application thereof |
WO2022213932A1 (en) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | Pyrrolopyrimidinone compound and application thereof |
CN114761410B (en) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | Pyrrolopyrimidinone compounds and application thereof |
CN113717053B (en) * | 2021-09-02 | 2023-10-27 | 合肥利夫生物科技有限公司 | Synthesis method of key intermediate of tyrosine kinase inhibitor |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
WO2007002433A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
US20080167338A1 (en) | 2006-12-21 | 2008-07-10 | Wayne Spevak | Compounds and methods for kinase modulation, and indications therefor |
US20090076046A1 (en) | 2006-11-22 | 2009-03-19 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US20090286783A1 (en) | 2008-05-19 | 2009-11-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2010104973A1 (en) | 2009-03-11 | 2010-09-16 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
EP1534340B1 (en) * | 2002-09-06 | 2011-11-16 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
EP1558751A4 (en) | 2002-09-16 | 2007-08-22 | Plexxikon Inc | Crystal structure of pim-1 kinase |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
US20050170431A1 (en) | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
DK1648867T3 (en) | 2003-07-17 | 2013-12-16 | Plexxikon Inc | PPAR ACTIVE CONNECTIONS |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
CN1925855B (en) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | Compounds and methods for development of Ret modulators |
US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
US7585859B2 (en) | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
JP2008512380A (en) | 2004-09-03 | 2008-04-24 | プレキシコン,インコーポレーテッド | PDE4B inhibitor |
JP2008521831A (en) | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | PPAR active compounds |
JP2008521829A (en) | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | PPAR active compounds |
US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
BRPI0610066A2 (en) | 2005-05-17 | 2010-05-25 | Plexxikon Inc | compounds that modulate c-kit and c-fms activity and uses for these |
KR20080047591A (en) | 2005-09-07 | 2008-05-29 | 플렉시콘, 인코퍼레이티드 | 1,3-disubstituted indole derivatives for use as ppar modulators |
EP1931658A2 (en) | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
CA2621406A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
RU2009114745A (en) * | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | BIOMARKERS INTENDED FOR IDENTIFICATION OF DIRECTED MODULATION, EFFICIENCY OF RAF INHIBITORS, APPLICATIONS FOR THE DIAGNOSTIC AND / OR FORECASTING |
CN101641351A (en) | 2006-12-21 | 2010-02-03 | 普莱希科公司 | Be used for Compounds and methods for and indication thereof that kinases is regulated |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20090159A1 (en) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS |
MX2009009290A (en) | 2007-03-08 | 2009-09-10 | Plexxikon Inc | Ppar active compounds. |
JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
MY161861A (en) | 2009-03-11 | 2017-05-15 | Plexxikon Inc | Pyrrolo [2,3-] pyridine kinase inhibitors |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
CR20170089A (en) | 2009-04-03 | 2017-07-17 | Plexxikon Inc | PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP2013510166A (en) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | Compounds, methods and applications for kinase regulation |
RU2012125070A (en) | 2009-11-18 | 2013-12-27 | Плексксикон, Инк. | COMPOUNDS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
AU2010322114B2 (en) | 2009-11-18 | 2014-07-31 | Novartis Ag | Methods and compositions for treating solid tumors and other malignancies |
JP5815558B2 (en) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for kinase regulation and their indications |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
AU2012255275B2 (en) | 2011-05-17 | 2016-01-28 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
CN104981247A (en) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
SI2935248T1 (en) | 2012-12-21 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
PT2970265T (en) | 2013-03-15 | 2018-10-23 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
WO2014194127A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
-
2010
- 2010-11-18 RU RU2012125070/04A patent/RU2012125070A/en not_active Application Discontinuation
- 2010-11-18 MX MX2012005827A patent/MX2012005827A/en active IP Right Grant
- 2010-11-18 SG SG10201407718WA patent/SG10201407718WA/en unknown
- 2010-11-18 CN CN2010800616210A patent/CN102740698A/en active Pending
- 2010-11-18 WO PCT/US2010/057293 patent/WO2011063159A1/en active Application Filing
- 2010-11-18 ES ES10832209.0T patent/ES2627911T3/en active Active
- 2010-11-18 AU AU2010321883A patent/AU2010321883A1/en not_active Abandoned
- 2010-11-18 US US12/949,741 patent/US8673928B2/en active Active
- 2010-11-18 MY MYPI2012002212A patent/MY156210A/en unknown
- 2010-11-18 PE PE2012000671A patent/PE20121335A1/en not_active Application Discontinuation
- 2010-11-18 NZ NZ599872A patent/NZ599872A/en not_active IP Right Cessation
- 2010-11-18 EP EP10832209.0A patent/EP2501236B1/en active Active
- 2010-11-18 CN CN201610244552.6A patent/CN105906631A/en active Pending
- 2010-11-18 KR KR1020127015004A patent/KR20120097512A/en not_active Application Discontinuation
- 2010-11-18 BR BR112012011792A patent/BR112012011792A2/en not_active IP Right Cessation
- 2010-11-18 JP JP2012540066A patent/JP2013511541A/en active Pending
- 2010-11-18 CA CA2781287A patent/CA2781287C/en active Active
-
2012
- 2012-05-03 IL IL219567A patent/IL219567A0/en unknown
- 2012-05-17 CO CO12081901A patent/CO6551689A2/en unknown
- 2012-05-18 CL CL2012001303A patent/CL2012001303A1/en unknown
- 2012-06-11 MA MA34954A patent/MA33811B1/en unknown
-
2014
- 2014-03-17 US US14/216,980 patent/US9617267B2/en active Active
-
2016
- 2016-01-28 AU AU2016200485A patent/AU2016200485B2/en active Active
- 2016-04-26 JP JP2016088438A patent/JP6194389B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
WO2007002433A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
WO2007002325A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
US20090076046A1 (en) | 2006-11-22 | 2009-03-19 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US20080167338A1 (en) | 2006-12-21 | 2008-07-10 | Wayne Spevak | Compounds and methods for kinase modulation, and indications therefor |
US20090286783A1 (en) | 2008-05-19 | 2009-11-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2010104973A1 (en) | 2009-03-11 | 2010-09-16 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
Non-Patent Citations (15)
Title |
---|
"CURRENT PROTOCOLS IN NUCLEIC ACID CHEMISTRY", vol. 1, 2000, JOHN WILEY AND SONS |
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS AND WILKINS |
"Remington's Pharmaceutical Sciences", vol. 2, 1995, MACK PUBLISHING CO., pages: 1457 |
BALAK, CLIN CANCER RES., vol. 12, 2006, pages 6494 - 501 |
BEAUCAGE; IYER, TETRAHEDRON, vol. 48, 1992, pages 2223 - 2311 |
CRUMP, CURR PHARM DES, vol. 8, no. 25, 2002, pages 2243 - 2248 |
HARRISON; HARRISON ET AL.: "COMPENDIUM OF SYNTHETIC ORGANIC METHODS", vol. 1-8, 1971, JOHN WILEY AND SONS |
HOOD, J.D. ET AL., SCIENCE, vol. 296, 2002, pages 2404 |
JAISWAL ET AL., PLOS ONE, vol. 4, no. 5, 2009, pages E5717 |
KUNNIMALAIYAAN ET AL., ANTICANCER DRUGS, vol. 17, no. 2, 2006, pages 139 - 142 |
MARCH: "Advanced Organic Chemistry; Reactions. Mechanisms and Structure", 1994, MCGRAW HILL |
MCDERMOTT ET AL., PNAS, vol. 104, no. 50, 2007, pages 19936 - 19941 |
NIIHORI ET AL., NAT GENET, vol. 38, no. 3, 2006, pages 294 - 296 |
See also references of EP2501236A4 |
T.W. GREENE; P.G. WUTS: "PROTECTIVE GROUPS IN ORGANIC CHEMISTRY", 2006, WILEY |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9663517B2 (en) | 2009-04-03 | 2017-05-30 | Plexxikon Inc. | Compositions and uses thereof |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10813930B2 (en) | 2010-12-22 | 2020-10-27 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US10213427B2 (en) | 2010-12-22 | 2019-02-26 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2672967A4 (en) * | 2011-02-07 | 2014-08-20 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US11337976B2 (en) | 2011-02-07 | 2022-05-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2672967A1 (en) * | 2011-02-07 | 2013-12-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2013169531A1 (en) | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
US9695169B2 (en) | 2012-05-31 | 2017-07-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JP2015518051A (en) * | 2012-05-31 | 2015-06-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | Synthesis of pyrrolo [2,3-b] pyridine |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US10131667B2 (en) | 2012-06-13 | 2018-11-20 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9505765B2 (en) | 2012-07-26 | 2016-11-29 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment |
US9745311B2 (en) | 2012-08-10 | 2017-08-29 | Incyte Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US10758533B2 (en) | 2012-08-13 | 2020-09-01 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US10195196B2 (en) | 2012-08-13 | 2019-02-05 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US11229648B2 (en) | 2012-08-13 | 2022-01-25 | Novartis Ag | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions |
CN103626765A (en) * | 2012-08-27 | 2014-03-12 | 广东东阳光药业有限公司 | Substituted azaindole compound and salt, composition and application thereof |
CN103626765B (en) * | 2012-08-27 | 2016-08-10 | 广东东阳光药业有限公司 | Substituted azaindole compounds and salt, compositions and purposes |
CN104781260A (en) * | 2012-09-26 | 2015-07-15 | 拜耳制药股份公司 | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
WO2014048869A1 (en) * | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
WO2014048894A1 (en) * | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
CN104837841A (en) * | 2012-09-26 | 2015-08-12 | 拜耳制药股份公司 | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10040790B2 (en) | 2013-04-19 | 2018-08-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10947230B2 (en) | 2013-04-19 | 2021-03-16 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10450313B2 (en) | 2013-04-19 | 2019-10-22 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10421761B2 (en) | 2013-05-30 | 2019-09-24 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
EA030631B1 (en) * | 2013-07-31 | 2018-09-28 | Новартис Аг | 1,4-disubstituted pyridazine quinoline derivatives and methods for treating smn-deficiency-related conditions |
EP4105208A1 (en) * | 2013-07-31 | 2022-12-21 | Novartis AG | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
US11672799B2 (en) | 2013-07-31 | 2023-06-13 | Novartis Ag | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions |
WO2015017589A1 (en) * | 2013-07-31 | 2015-02-05 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10150783B2 (en) | 2015-01-23 | 2018-12-11 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10738048B2 (en) | 2015-02-20 | 2020-08-11 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9801889B2 (en) | 2015-02-20 | 2017-10-31 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10214528B2 (en) | 2015-02-20 | 2019-02-26 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10632126B2 (en) | 2015-02-20 | 2020-04-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10016438B2 (en) | 2015-02-20 | 2018-07-10 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10251892B2 (en) | 2015-02-20 | 2019-04-09 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN108699062A (en) * | 2015-12-23 | 2018-10-23 | 艾科尔公司 | THP trtrahydropyranyl amino-Pyrrolopyrimidine thion and its application method |
US11020400B2 (en) | 2015-12-23 | 2021-06-01 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TWI750645B (en) * | 2015-12-23 | 2021-12-21 | 美商亞奎里公司 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TWI694077B (en) * | 2015-12-23 | 2020-05-21 | 美商亞闊股份有限公司 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10933065B2 (en) | 2015-12-23 | 2021-03-02 | Arqule Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10245263B2 (en) | 2015-12-23 | 2019-04-02 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US12024517B2 (en) | 2018-05-04 | 2024-07-02 | Incyte Corporation | Salts of an FGFR inhibitor |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020239124A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
RU2824583C2 (en) * | 2019-05-31 | 2024-08-12 | Фочон Байосайенсиз, Лтд. | Substituted pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11897889B2 (en) | 2020-08-18 | 2024-02-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
US11905292B2 (en) | 2020-08-18 | 2024-02-20 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
US12076322B2 (en) | 2022-08-25 | 2024-09-03 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US12083124B2 (en) | 2023-01-26 | 2024-09-10 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
Also Published As
Publication number | Publication date |
---|---|
BR112012011792A2 (en) | 2015-10-13 |
JP6194389B2 (en) | 2017-09-06 |
EP2501236A4 (en) | 2013-05-15 |
JP2016185958A (en) | 2016-10-27 |
NZ599872A (en) | 2014-08-29 |
AU2016200485A1 (en) | 2016-02-18 |
US8673928B2 (en) | 2014-03-18 |
PE20121335A1 (en) | 2012-10-12 |
JP2013511541A (en) | 2013-04-04 |
CL2012001303A1 (en) | 2012-10-05 |
US20110152258A1 (en) | 2011-06-23 |
RU2012125070A (en) | 2013-12-27 |
CA2781287C (en) | 2018-07-31 |
ES2627911T3 (en) | 2017-08-01 |
EP2501236A1 (en) | 2012-09-26 |
MY156210A (en) | 2016-01-29 |
CN102740698A (en) | 2012-10-17 |
MX2012005827A (en) | 2012-06-19 |
SG10201407718WA (en) | 2015-01-29 |
MA33811B1 (en) | 2012-12-03 |
AU2010321883A1 (en) | 2012-05-31 |
CN105906631A (en) | 2016-08-31 |
IL219567A0 (en) | 2012-06-28 |
US20140288070A1 (en) | 2014-09-25 |
CA2781287A1 (en) | 2011-05-26 |
US9617267B2 (en) | 2017-04-11 |
EP2501236B1 (en) | 2017-03-29 |
AU2016200485B2 (en) | 2017-09-28 |
CO6551689A2 (en) | 2012-10-31 |
KR20120097512A (en) | 2012-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016200485B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
US9440969B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
AU2010315126B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
US8901301B2 (en) | Pyrrolo[2,3-]pyridine kinase inhibitors | |
US8198273B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
EP2560972B1 (en) | Compounds and methods for kinase modulation, and indications therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080061621.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10832209 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219567 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010321883 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4303/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2781287 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012540066 Country of ref document: JP Ref document number: 12081901 Country of ref document: CO Ref document number: 000671-2012 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012001303 Country of ref document: CL Ref document number: 12012500981 Country of ref document: PH Ref document number: MX/A/2012/005827 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2010321883 Country of ref document: AU Date of ref document: 20101118 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127015004 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201207259 Country of ref document: UA |
|
REEP | Request for entry into the european phase |
Ref document number: 2010832209 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012125070 Country of ref document: RU Ref document number: 2010832209 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201002337 Country of ref document: TH |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012011792 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012011792 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120517 |